date,open,high,low,close,volume,title,description,title_sentiment,desc_sentiment,daily_change_pct,market_sentiment,next_day_change_pct,next_day_sentiment
2018-01-24 18:00:49.874,323.25,323.4,307.0,312.0,575876.0,"Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl","EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.",neutral,positive,-3.480278422273782,negative,0.9920000000000072,positive
2018-03-26 18:00:18.448,298.0,306.5,295.62,300.0,817464.0,Syngene enters into pact with GSK for drug discovery services,"Syngene International, a global contract research services company, has entered into an R&D agreement with healthcare major GSK.The multi-year agreement will focus on accelerating the discovery of",positive,positive,0.6711409395973155,neutral,-0.5266666666666614,neutral
2018-03-27 13:00:47.133,300.0,300.17,290.0,298.42,175850.0,Syngene inks pact with GSK for new drug discovery,"Syngene International on Monday signed a research and development agreement with global healthcare company GSK. As part of the agreement, Syngene will set up a customised discovery research laboratory",positive,positive,-0.5266666666666614,neutral,-1.6666666666666667,negative
2018-03-27 13:01:41.185,300.0,300.17,290.0,298.42,175850.0,Biocon's Syngene inks pact with GSK for new drug discovery,"Biocon's contract research arm Syngene International today said it has inked a drug discovery agreement with global drug firm GSK.
The multi-year R&D agreement between the two companies will focus on accelerating the discovery of new drug candidates",positive,positive,-0.5266666666666614,neutral,-1.6666666666666667,negative
2018-04-26 13:34:03.508,321.95,326.3,306.0,309.75,342730.0,Syngene International Q4 net rises 8% to Rs 84 crore,,positive,neutral,-3.789408293213228,negative,0.0,neutral
2018-05-18 18:00:19.694,302.0,305.9,301.0,302.8,185162.0,Biocon sells 1.88% stake in Syngene for Rs230 crore,"Syngene International promoter Biocon says it has sold 37,65,574 equity shares of Syngene amounting to 1.88% through open market sale",neutral,neutral,0.2649006622516594,neutral,-1.2728459530026035,negative
2018-05-30 18:01:33.137,302.75,306.38,296.12,299.5,316704.0,Syngene International up 1% on partnership with Zumutor Biologics,The company has entered into a non-exclusive partnering agreement with Zumutor Biologics to access Zumutor’s proprietary naive human phage/yeast display library.,neutral,positive,-1.0734929810074318,negative,-0.0166638893517784,neutral
2018-05-30 23:01:14.247,302.75,306.38,296.12,299.5,316704.0,Syngene International inks pact with Zumutor Biologics,Syngene International on Wednesday informed the bourses that it has entered into a pact with US-based Zumutor Biologics for biotherapeutic antibody discovery services. As part of the non-exclusive par,positive,positive,-1.0734929810074318,negative,-0.0166638893517784,neutral
2018-07-03 18:01:27.686,308.0,309.42,298.67,302.95,117162.0,"Movers & shakers: Volumes of Tata Comm, Syngene rose the most in last 5 days","Tata Communications was trading with volumes of 1,034,533 shares, compared to its five day average of 13,786 shares, an increase of 7,404.12 percent.  Syngene International was trading with volumes of 153,013 shares, compared to its five day average of 4,920 shares, an increase of 3,010.15 percent.",positive,positive,-1.6396103896103933,negative,-0.6109643328930061,neutral
2018-07-23 23:02:25.504,301.88,303.0,296.5,298.05,200856.0,Biocon arm Syngene expands scope of R&D work with Baxter Health Corp,"Syngene International, the contract research arm of Biocon has expanded the scope of its research and development (R&D) efforts with Baxter Health Corporation.This development comes on the heels o",positive,positive,-1.2687160461110325,negative,-1.9607843137254828,negative
2018-07-25 23:00:31.241,287.5,291.25,282.5,288.0,204004.0,Syngene International Q1 net profit up 6% at Rs 66 crore,Standalone total income stood at Rs 424.8 crore for the quarter under consideration. It was Rs 308.3 crore in the corresponding period previous fiscal.,positive,neutral,0.1739130434782608,neutral,0.0860585197934595,neutral
2018-09-25 13:02:33.338,312.02,317.5,308.6,312.0,64878.0,Syngene International COO Manoj Nerurkar resigns,"Biocon’s contract research arm Syngene International on Tuesday announced the resignation of Manoj Nerurkar as Chief Operating Officer with effect from October 1, 2018. Nerurkar, however, will continu",neutral,neutral,-0.006409845522717,neutral,-2.418964683115626,negative
2018-10-12 18:01:32.193,297.2,300.48,292.2,293.45,44938.0,Syngene International Q2 PAT seen up 22.1% YoY to Rs. 93.9 cr: ICICI Direct,"Net Sales are expected to increase by 24.8 percent Y-o-Y (up 3 percent Q-o-Q) to Rs. 418.2 crore, according to ICICI Direct.",positive,positive,-1.2617765814266486,negative,0.7548574910297072,neutral
2018-10-25 13:03:25.373,291.48,292.4,282.48,284.75,85436.0,"Syngene Intl Standalone September 2018 Net Sales at Rs 418.60 crore, up 24.88% Q-o-Q","Syngene Intl Standalone September 2018 Net Sales at Rs 418.60 crore, up 24.88% Q-o-Q",positive,positive,-2.3089062714423005,negative,0.6135607321131384,neutral
2018-10-25 18:00:47.082,291.48,292.4,282.48,284.75,85436.0,"Q2 Results: Margins Affected By Expansion Plans, Says Syngene International",The company’s plans to expand in U.S. and Europe and investments to improve quality standards impacted its margin growth for Q2.,neutral,negative,-2.3089062714423005,negative,0.6135607321131384,neutral
2019-01-11 23:02:46.106,273.15,273.48,269.5,271.0,92108.0,Syngene International Q3 PAT seen up 1.5% YoY to Rs. 83.3 cr: ICICI Direct,"Net Sales are expected to increase by 11.2 percent Y-o-Y (up 3 percent Q-o-Q) to Rs. 431.1 crore, according to ICICI Direct.",positive,positive,-0.7871133077063802,neutral,0.1672240802675543,neutral
2019-01-22 23:01:58.311,292.5,295.5,285.27,290.0,723194.0,Syngene Q3 net profit up 6% to Rs 87 cr,"The company had posted a net profit of Rs 82 crore for the corresponding period of the previous fiscal, Syngene International said in a filing to BSE.",positive,positive,-0.8547008547008548,neutral,3.2190342897130817,positive
2019-01-23 13:01:54.032,285.8,297.5,285.8,295.0,1698672.0,"Syngene Intl Standalone December 2018 Net Sales at Rs 467.10 crore, up 20.48% Y-o-Y","Syngene Intl Standalone December 2018 Net Sales at Rs 467.10 crore, up 20.48% Y-o-Y",positive,positive,3.2190342897130817,positive,1.2586206896551646,positive
2019-01-24 23:01:07.757,290.0,300.0,290.0,293.65,196018.0,Broker's call: Syngene International (Add),YES SecuritiesSyngene International (Add)CMP: ₹590.5Target: ₹620Syngene International reported another strong quarter of growth with revenues up 21 per cent y-o-y driven by client mining and acquisiti,neutral,positive,1.2586206896551646,positive,-3.748299319727885,negative
2019-04-22 13:01:31.218,299.95,302.0,296.5,300.88,132446.0,Syngene International rises 5% as board to consider bonus issue,"The share touched its 52-week high Rs 699.80 and 52-week low Rs 509.30 on 25 April, 2018 and 11 December, 2018, respectively. ",neutral,positive,0.3100516752792154,neutral,-0.7605820105819956,neutral
2019-04-24 10:01:33.223,302.4,303.0,298.5,300.1,147526.0,"What to watch: Syngene Int’l: Focus on results, bonus meet","The stock of Syngene International will remain in focus, as the company will declare its quarter as well as annual financial results for the period ended March 2019. The board will also consider a pro",neutral,positive,-0.7605820105819956,neutral,-1.6723273491832311,negative
2019-04-25 13:01:26.266,306.98,307.0,302.62,304.5,632820.0,"Syngene Intl Standalone March 2019 Net Sales at Rs 533.90 crore, up 30.51% Y-o-Y","Syngene Intl Standalone March 2019 Net Sales at Rs 533.90 crore, up 30.51% Y-o-Y",positive,positive,-0.8078702195582833,neutral,1.2612375275792749,positive
2019-04-25 23:02:37.844,306.98,307.0,302.62,304.5,632820.0,Company news: Syngene International,The board of Syngene International has approved the issue of bonus shares by capitalisation of free reserves in the ratio of 1:1. The company will intimate the record date for determining eligible sha,neutral,neutral,-0.8078702195582833,neutral,1.2612375275792749,positive
2019-05-01 23:00:29.454,307.5,307.7,302.5,302.5,1378140.0,"Add  Syngene International, target Rs  650: Yes Securities  ",Add  Syngene International at a price target of Rs  650.,neutral,neutral,-1.6260162601626018,negative,-0.2800658978583271,neutral
2019-07-24 18:00:33.299,310.0,314.1,301.1,308.0,175437.0,"Syngene Intl Standalone June 2019 Net Sales at Rs 420.90 crore, up 3.67% Y-o-Y","Syngene Intl Standalone June 2019 Net Sales at Rs 420.90 crore, up 3.67% Y-o-Y",positive,positive,-0.6451612903225806,neutral,0.1602564102564102,neutral
2019-07-25 13:01:18.958,312.0,313.1,307.5,312.5,36659.0,Syngene International stock down 1%; PAT at Rs72cr,"The company posted quarterly revenue of Rs441cr, an increase of 4% from Rs425cr in the corresponding quarter of FY19.",negative,positive,0.1602564102564102,neutral,2.0012911555842443,positive
2019-08-08 23:02:51.387,316.1,318.0,310.5,312.55,35440.0,Company news: Syngene International,Syngene International on Thursday said it has received an additional interim payment of ₹97 crore from an insurance company for the damage caused during the fire at its premises in December 2016. The,neutral,positive,-1.1230623220499878,negative,-1.6340916372957457,negative
2019-10-22 23:00:58.486,333.95,344.35,330.0,331.4,220708.0,Syngene International Q2 profit up 64% to Rs 128 cr,"Total income stood at Rs 485.2 crore for the quarter under review as against Rs 436.8 crore for the same period a year ago, it added.

",positive,neutral,-0.7635873633777546,neutral,-1.7125837676842888,negative
2019-10-23 13:04:19.561,335.75,335.75,327.25,330.0,97296.0,"Syngene Intl Standalone September 2019 Net Sales at Rs 464.60 crore, up 10.99% Y-o-Y","Syngene Intl Standalone September 2019 Net Sales at Rs 464.60 crore, up 10.99% Y-o-Y",positive,positive,-1.7125837676842888,negative,0.855745721271397,neutral
2019-12-02 13:02:32.697,319.1,325.0,308.4,308.4,240558.0,Syngene International to appoint Sibaji Biswas as CFO,"Biswas will succeed M B Chinappa, current CFO, who will stay within the Biocon group of companies and join Biocon Biologics India Ltd in a new role.",neutral,neutral,-3.353180821059243,negative,-0.0811688311688311,neutral
2019-12-02 18:04:27.466,319.1,325.0,308.4,308.4,240558.0,Syngene appoints former Vodafone executive Sibaji Biswas as CFO,"Biswas was the CFO and board member for Vodafone Romania .Incorporated in 1993, Syngene is a contract research and manufacturing organization that supports research and development programmes for its clients in industries like pharma, agrochemicals, nutrition and animal health",neutral,neutral,-3.353180821059243,negative,-0.0811688311688311,neutral
2020-01-07 10:02:22.746,321.1,321.3,306.65,309.0,233843.0,Biocon appoints M.B. Chinappa as CFO of arm Biocon Biologics,"Mr. M.B. Chinappa joins Biocon Biologics from Biocon’s subsidiary company Syngene International Ltd, where he was President (Finance) and CFO since 2008.",neutral,neutral,-3.768296480847095,negative,0.3581895148160097,neutral
2020-01-07 10:03:23.451,321.1,321.3,306.65,309.0,233843.0,Biocon appoints MB Chinappa as CFO of Biocon Biologics,"Chinappa joins Biocon Biologics from another subsidiary company Syngene International, where he was President (Finance) and CFO since 2008",neutral,neutral,-3.768296480847095,negative,0.3581895148160097,neutral
2020-01-07 18:03:14.839,307.1,311.0,305.1,308.2,130842.0,"Chinappa joins Biocon Biologics from Biocon's subsidiary company Syngene International Ltd, where he was President (Finance) and CFO since 2008, the company said in a filing to the BSE.","Chinappa joins Biocon Biologics from Biocon's subsidiary company Syngene International Ltd, where he was President (Finance) and CFO since 2008, the company said in a filing to the BSE.",neutral,neutral,0.3581895148160097,neutral,-0.6430868167202572,neutral
2020-01-07 23:03:06.048,307.1,311.0,305.1,308.2,130842.0,Biocon Biologics IPO: Syngene encore on the cards,"Syngene, which was listed in August 2015, raised Rs 550 crore. The IPO was subscribed 32 times. Incidentally, True North was an investor in Syngene before it was listed.",neutral,positive,0.3581895148160097,neutral,-0.6430868167202572,neutral
2020-01-22 18:04:27.542,307.0,312.0,303.1,304.65,549213.0,"BRIEF-India's Syngene International Dec Quarter Consol Profit Rises - Investing.com India
",Read BRIEF-India's Syngene International Dec Quarter Consol Profit Rises By Reuters,neutral,neutral,-0.7654723127035905,neutral,1.1532125205930808,positive
2020-01-22 23:03:04.497,307.0,312.0,303.1,304.65,549213.0,Syngene International Q3 profit up 6% to Rs 92cr,"Total income rose to Rs 539 crore for the quarter under review as against Rs 484 crore for the same period a year ago.

",positive,positive,-0.7654723127035905,neutral,1.1532125205930808,positive
2020-01-22 23:03:18.030,307.0,312.0,303.1,304.65,549213.0,Syngene Q3 profit rises 6% with 11% increase in revenue,Strong performances from discovery and development services boosted contract research and manufacturing company Syngene International Ltd’s net profit by 6 per cent to ₹92 crore in the third quarter,positive,positive,-0.7654723127035905,neutral,1.1532125205930808,positive
2020-01-23 10:00:55.354,307.0,312.0,303.1,304.65,549213.0,Syngene reports 6% yoy rise in Q3 net profit,"The company posted a quarterly revenue of Rs539cr, an increase of 11% from the corresponding quarter last year.",positive,positive,-0.7654723127035905,neutral,1.1532125205930808,positive
2020-02-17 23:00:34.858,307.45,308.0,304.0,307.2,50137.0,"Syngene, Biological E facilities opened",Facility to offer Discovery Chemistry services,neutral,neutral,-0.0813140348024069,neutral,0.1951854261548545,neutral
2020-02-17 23:00:43.417,307.45,308.0,304.0,307.2,50137.0,Syngene sets up new R&D centre in Genome Valley,"Syngene International Ltd, a global contract research organisation, has commissioned the first phase of its new R&amp;amp;D centre in Genome Valley, Hyderabad.The facility is spread across 52,000 sq.",neutral,neutral,-0.0813140348024069,neutral,0.1951854261548545,neutral
2020-02-17 23:00:51.606,307.45,308.0,304.0,307.2,50137.0,Syngene commissions phase-1 of new R&D centre in Hyderabad,This is the company's first operational research centre outside Bengaluru.,neutral,neutral,-0.0813140348024069,neutral,0.1951854261548545,neutral
2020-02-17 23:02:35.967,307.45,308.0,304.0,307.2,50137.0,Syngene announces commissioning of first phase of R&D center in Hyderabad,Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet,neutral,neutral,-0.0813140348024069,neutral,0.1951854261548545,neutral
2020-02-19 10:03:28.805,307.4,310.5,304.0,308.0,39543.0,"Syngene International Limited, a leading global contract research organisation, announced the commissioning of the first phase of its new R&D centre in Hyderabad","Syngene International Limited, a leading global contract research organisation, announced the commissioning of the first phase of its new R&D centre in Hyderabad",positive,positive,0.1951854261548545,neutral,0.065189048239892,neutral
2020-03-20 10:02:49.812,241.15,242.65,236.0,239.25,409551.0,Syngene International starts operations at Mangalore facility,Syngene International has commenced operations at its new manufacturing facility at Mangalore.,neutral,neutral,-0.787891353929092,neutral,-2.1715288440447416,negative
2020-04-24 19:36:00.000,310.0,315.3,305.0,305.35,429387.0,MyLab partners with Biocon’s research arm Syngene to produce coronavirus testing kits,"In a bid to scale up production and escalate faster delivery of COVID-19 testing kits, Pune-based molecular diagnostics company Mylab Discovery Solutions has entered into partnered with Syngene International",neutral,positive,-1.499999999999993,negative,-3.761755485893417,negative
2020-04-24 22:29:30.000,310.0,315.3,305.0,305.35,429387.0,Mylab collaborates with Kiran Mazumdar Shaw’s Syngene International,Pune-based molecular diagnostics company Mylab Discovery Solutions is collaborating with Syngene International to source raw material for its Covid-19 testing kits.A publicly listed research services,positive,positive,-1.499999999999993,negative,-3.761755485893417,negative
2020-04-28 08:28:00.000,318.3,324.0,307.0,309.45,363778.0,Syngene International unveils Covid-19 testing centre to help Bengaluru Hospital; stocks up 4.50%,"For this new facility, the company appointed a team of trained scientists to perform these tests as per the guidelines.",positive,neutral,-2.7803958529689043,negative,-1.025641025641022,negative
2020-04-28 11:45:00.000,318.3,324.0,307.0,309.45,363778.0,Trending stocks: Syngene International stock price up nearly 1%,Shares of Syngene International Ltd. traded 0.63 per cent up in trade at 11:40AM on Tuesday .,positive,positive,-2.7803958529689043,negative,-1.025641025641022,negative
2020-05-12 08:57:43.000,318.0,325.0,311.25,322.0,473177.0,"Stocks in focus: RIL, IRCTC, Nestle India, Bandhan Bank among stocks to remain in action today","Havells, IndiaMart, Syngene, Bandhan Bank and Nestle India are among 11 companies which are scheduled to announce their March quarter earnings on Tuesday.",neutral,neutral,1.257861635220126,positive,-2.1021021021021022,negative
2020-05-13 17:26:00.000,328.8,342.9,326.0,342.3,650122.0,Syngene International Q4 results: Profit up 20% to Rs 120 crore,The company had posted a net profit of Rs 100 crore for the corresponding period of the previous fiscal.,positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-13 18:31:00.000,328.8,342.9,326.0,342.3,650122.0,Syngene International Q4 profit up 20% to Rs 120 crore,"The company had posted a net profit of Rs 100 crore for the corresponding period of the previous fiscal, Syngene International said in a statement.",positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-13 19:01:21.000,328.8,342.9,326.0,342.3,650122.0,"Syngene International Q4 profit up 20% to Rs 120 cr after robust growth in main divisions; income rises - Business News , Firstpost","Shares of Syngene International Ltd closed at Rs 325.30 on BSE, up 1.91 percent from the previous close.",positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-14 10:13:00.000,328.8,342.9,326.0,342.3,650122.0,Syngene International gains 5% on healthy March quarter results,The companys profit after tax rose 20 per cent to Rs 120 crore relative to last years profit of Rs 100 crore.,positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-14 11:09:00.000,328.8,342.9,326.0,342.3,650122.0,Trending stocks: Syngene International shares gain over 2% - The Economic Times,Shares of Syngene International Ltd. traded 2.43 per cent up in trade at 11:06AM on Thursday.,positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-14 11:53:50.000,328.8,342.9,326.0,342.3,650122.0,Syngene International shares jump 5 per cent after Q4 earnings,Shares of Syngene International jumped 5 per cent on Thursday after the company reported a 20 per cent rise in its consolidated net profit for the quarter ended March 2020.The company’s stock gained 4,positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-14 11:58:00.000,328.8,342.9,326.0,342.3,650122.0,Syngene International shares jump 5% after Q4 earnings,"The company on Wednesday reported a 20 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended March 31, 2020, driven by robust growth in its main divisions.",positive,positive,4.105839416058394,positive,-0.7600116924875834,neutral
2020-05-15 14:57:00.000,342.1,347.15,332.45,339.5,419649.0,Buy Syngene International; target of Rs 390: ICICI Direct,"ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 390 in its research report dated May 14, 2020.",neutral,positive,-0.7600116924875834,neutral,-1.4705882352941175,negative
2020-05-21 13:47:00.000,360.0,373.9,350.0,358.6,501236.0,"JB Chemicals & Pharma, Syngene International hit all-time highs","The stock of Syngene International has soared 24 per cent during the past month, as against a 2 per cent rise in the S&P BSE Sensex.",positive,positive,-0.3888888888888825,neutral,-2.8278347657332934,negative
2020-06-02 20:17:22.000,389.2,389.95,366.6,369.0,1019878.0,"Biocon arm Syngene develops ELISA test kits, ties up with HiMedia for production",Syngene claims that the testing kit has a capacity to test multiple samples together in a single run and generate results within 3 hours,neutral,neutral,-5.190133607399792,negative,-1.7520215633423182,negative
2020-06-03 07:50:42.000,389.2,389.95,366.6,369.0,1019878.0,"In Pics | Stocks In The News: Britannia, InterGlobe Aviation, Kotak Bank, Just Dial",Lupin | ADF Foods | Coromandel International | Quess Corp | Minda Industries | Syngene International | Tribhovandas Bhimji Zaveri | Granules India | Everest Organics | Transport Corporation of India | Axita Cotton are also in focus today.,neutral,neutral,-5.190133607399792,negative,-1.7520215633423182,negative
2020-06-03 08:37:00.000,389.2,389.95,366.6,369.0,1019878.0,"Stocks to watch: IndiGo, Britannia, RIL, Eris Life, Lupin, Syngene Int’l",Heres a list of the top stocks that may remain in focus today,neutral,neutral,-5.190133607399792,negative,-1.7520215633423182,negative
2020-06-03 09:07:45.000,389.2,389.95,366.6,369.0,1019878.0,"Stocks in focus: RIL, Aurobindo Pharma, Syngene International, Britannia, IndiGo, Lupin","Orient Hotels, DCM Shriram, BPCL, Aurobindo Pharma, MAS Financial Services, Cholamandalam Investment and Dishman Carbogen are among 15 companies which are scheduled to announce their March quarter earnings today",neutral,neutral,-5.190133607399792,negative,-1.7520215633423182,negative
2020-06-03 09:36:00.000,389.2,389.95,366.6,369.0,1019878.0,Covid-19: Biocon’s Syngene partners with HiMedia Labs for Elisa test kits,"These test kits, developed indigenously, test the presence of SARS-COV-2 antibodies and confirm if a patient has been exposed to the coronavirus",neutral,neutral,-5.190133607399792,negative,-1.7520215633423182,negative
2020-06-03 15:44:00.000,371.0,374.0,362.2,364.5,264967.0,Syngene International soars 5% on Covid-19 test kit deal with HiMedia,The kit has the capacity to test samples together in a single run and generate results within 3 hours.,positive,neutral,-1.7520215633423182,negative,-0.4054054054054054,neutral
2020-06-03 16:51:00.000,371.0,374.0,362.2,364.5,264967.0,Syngene ties up with HiMedia Laboratories to manufacture ELISA test kits for COVID-19; stock up 1%,Syngene has indigenously developed an anti-COV-2 IgG ELISA (Enzyme-Linked Immunosorbent Assay) at its research facility in Bengaluru.,positive,neutral,-1.7520215633423182,negative,-0.4054054054054054,neutral
2020-06-04 15:52:27.000,370.0,373.6,365.2,368.5,387114.0,Syngene pitches in with indigenous antibody test kits,Syngene International has indigenously developed its own ELISA antibody testing kits at its research facility in Bengaluru. The company has partnered with bioscience firm HiMedia Laboratories for manu,neutral,positive,-0.4054054054054054,neutral,0.2941963091735819,neutral
2020-06-16 10:46:00.000,371.2,373.55,365.35,368.5,561082.0,"US revokes decision to treat Covid-19 patients with hydroxychloroquine; jolt for Zydus Cadila, Ipca Lab","About six Indian companies like Cipla, Jubilant, Hetero, Syngene, Dr Reddy’s and Zydus Cadila were licensed to make and distribute the drug in over 120 geographies",neutral,neutral,-0.7273706896551694,neutral,-0.3940217391304317,neutral
2020-07-07 03:23:00.000,436.0,475.45,432.0,439.5,1051517.0,Syngene International gets upgraded rating from Crisil; stock trades flat,The company’s rating got upgraded to stable outlook from the positive outlook (AA).,positive,positive,0.8027522935779817,neutral,-2.585327134595754,negative
2020-07-10 17:32:00.000,432.0,450.0,430.3,442.0,2554374.0,Avoid cos with pricing control or loan waivers: Chakri Lokapriya - The Economic Times,"DRL, Glenmark, Syngene or Pfizer have a fairly good growth profile over the next few years.",neutral,positive,2.314814814814815,positive,-3.088888888888884,negative
2020-07-20 07:16:00.000,427.0,434.5,420.85,422.95,426472.0,"Stocks in the news: HDFC Bank, Vodafone Idea, Future Retail, YES Bank, SBI Card and Cadila Healthcare","ACC, Bombay Dyeing, SBI Card, Syngene and Den Networks are scheduled to announce their June quarter earnings on Monday.",neutral,neutral,-0.9484777517564428,negative,-0.6459189665296535,neutral
2020-07-21 08:05:00.000,425.75,429.8,420.0,423.0,451972.0,"Stocks in the news: Axis Bank, HUL, Bajaj Finance, ACC, Vodafone Idea and SBI Card","DCM Shriram, IndiaMART InterMESH and Syngene International are slated to announce their June quarter earnings on Tuesday.",neutral,neutral,-0.6459189665296535,neutral,0.2751196172248749,neutral
2020-07-21 08:52:00.000,425.75,429.8,420.0,423.0,451972.0,"Important results today: Hindustan Unilever, Axis Bank, Bajaj Finance, Bajaj Finserv","ICICI Prudential Life Insurance Company, SBI Life Insurance Company, IndiaMART InterMESH, Crisil, DCM Shriram and Syngene International are slated to announce their June quarter earnings on Tuesday.",neutral,neutral,-0.6459189665296535,neutral,0.2751196172248749,neutral
2020-07-21 08:58:35.000,425.75,429.8,420.0,423.0,451972.0,"Stocks in focus: RIL, Airtel, Vodafone Idea, Britannia, Jubilant Life Sciences, HUL, Axis Bank, Bajaj Finance","Hindustan Unilever, Axis Bank, Bajaj Finance, ICICI Prudential Life, Bajaj Finserv, Crisil, DCM Shriram, IndiaMART InterMESH and Syngene International are slated to announce their June quarter earnings later in the day today",neutral,neutral,-0.6459189665296535,neutral,0.2751196172248749,neutral
2020-07-22 01:03:00.000,418.0,424.3,408.0,419.15,363776.0,Syngene’s CEO Jonathan Hunt sees growth returning in Q2; PAT drops by 19% yoy in Q1,"The profit after tax (PAT) margin was at 13%, lower from 16% of Q1FY20.",neutral,negative,0.2751196172248749,neutral,4.22335265586183,positive
2020-07-22 07:00:00.000,418.0,424.3,408.0,419.15,363776.0,Syngene International consolidated net profit declines 19.44% in the June 2020 quarter,Sales rise 0.17% to Rs 421.60 crore,negative,positive,0.2751196172248749,neutral,4.22335265586183,positive
2020-07-22 08:49:59.000,418.0,424.3,408.0,419.15,363776.0,Covid impact: Syngene profits down 19.44 per cent in Q1,Hit by temporary suspension of operations during lockdown,negative,neutral,0.2751196172248749,neutral,4.22335265586183,positive
2020-07-22 10:25:00.000,418.0,424.3,408.0,419.15,363776.0,Syngene Intl corrects after Q1 PAT skids 19% to Rs 58 cr,Syngene International fell 1.03% to Rs 418.90 after consolidated net profit dropped 19.4% to Rs 58 crore on 0.2% increase in net sales to Rs 421.60 crore in Q1 June 2020 over Q1 June 2019.,neutral,negative,0.2751196172248749,neutral,4.22335265586183,positive
2020-07-22 19:37:00.000,422.65,441.0,421.05,440.5,586671.0,"After a muted Q1, Syngene guides for double-digit top line growth","Despite the pressure on revenues in the June quarter, the company reported steady operating performance.",positive,positive,4.22335265586183,positive,5.281531531531529,positive
2020-07-23 21:45:33.000,444.0,472.95,441.5,467.45,1940874.0,"ICICI Direct: Syngene International Q1 Reports Steady Numbers Despite Covid-19, Positive Outlook","ICICI Direct: Syngene International Q1 Reports Steady Numbers Despite Covid-19, Positive Outlook",neutral,neutral,5.281531531531529,positive,-2.355460385438972,negative
2020-07-24 12:53:00.000,444.0,472.95,441.5,467.45,1940874.0,Syngene International rallies 13% in two days; stock nears record high,ICICI Securities expects Syngenes revenues to be back on track as the company is currently operating at 90 per cent capacity.,positive,positive,5.281531531531529,positive,-2.355460385438972,negative
2020-08-13 10:20:14.000,493.3,494.0,481.2,489.0,510957.0,"Covid-19: India’s cheapest remdesivir version to cost ₹2,800 per vial","Zydus is the fifth company to launch a copy of the antiviral in India .Gilead has also entered into licensing agreements with Dr.Reddy’s Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India",neutral,neutral,-0.8716805189539857,neutral,-0.1020824826459779,neutral
2020-08-13 17:10:00.000,489.8,502.0,483.05,489.3,590068.0,"Zydus Cadila launches India’s cheapest remdesivir version at Rs 2,800 per 100 mg vial","Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd. Gilead has also entered into licensing agreements with Dr.Reddy’s Laboratories Ltd and Syngene International Ltd to make remdesivir for distribu…",positive,neutral,-0.1020824826459779,neutral,-1.944106925880928,negative
2020-08-26 06:45:00.000,508.8,512.95,487.85,491.9,698702.0,Syngene International (₹503.8): Buy,The stock of Syngene International breached the psychological hurdle of ₹500 on Tuesday. It advanced and registered fresh all-time high of ₹512.8 before closing at ₹503.8. The fresh breakout has stren,neutral,positive,-3.3215408805031514,negative,-1.4668689934243804,negative
2020-09-09 20:11:00.000,467.7,494.5,463.2,474.25,2092888.0,Syngene-HiMedia’s Elisa test kit for Covid-19 gets ICMR approval,The product will be launched once it receives approval from the Central Drugs Standard Control Organisation next,positive,neutral,1.4004703870002162,positive,-0.367068694284216,neutral
2020-09-10 09:20:00.000,467.7,494.5,463.2,474.25,2092888.0,Syngene Intl gallops after ICMR approval for COVID-19 antibody test kit,"Syngene International jumped 5.74% to Rs 479.80 after the company said it received ICMR approval for HiMedia-Syngenes COVID-19 antibody test kit, ELISafe 19.",neutral,positive,1.4004703870002162,positive,-0.367068694284216,neutral
2020-09-10 09:59:00.000,467.7,494.5,463.2,474.25,2092888.0,Syngene International skyrockets 7% as ICMR approves COVID-19 antibody test kit ‘ELISafe 19’,The kit was developed by Syngene at its research facility in Bengaluru.,neutral,neutral,1.4004703870002162,positive,-0.367068694284216,neutral
2020-09-10 10:00:00.000,467.7,494.5,463.2,474.25,2092888.0,Syngene International surges 9% on ICMR nod for its Covid-19 test kit,The product will be launched once it receives approval from the Central Drugs Standard Control Organisation (CDSCO) next.,positive,neutral,1.4004703870002162,positive,-0.367068694284216,neutral
2020-09-10 11:02:00.000,467.7,494.5,463.2,474.25,2092888.0,Syngene International shares jump 7% on ICMR nod for COVID-19 antibody test kit,The ELISafe 19TM antibody test kit has a sensitivity of 100 percent and specificity of 99 percent.,positive,neutral,1.4004703870002162,positive,-0.367068694284216,neutral
2020-09-10 15:16:36.000,476.75,492.0,467.6,475.0,514592.0,Volumes soar at Syngene International Ltd counter,"Syngene International Ltd clocked volume of 18.71 lakh shares by 14:19 IST on NSE, a 4.66 times surge over two-week average daily volume of 4.02 lakh shares",neutral,positive,-0.367068694284216,neutral,-4.689998223485517,negative
2020-09-10 15:22:43.000,476.75,492.0,467.6,475.0,514592.0,ICMR approves HiMedia-Syngene’s Elisa test kit for Covid-19,"HiMedia Laboratories, a bioscience company and Syngene International, an integrated R&amp;D services company, have collaborated to manufacture ELISafe 19, an IgG-based Elisa test kit for Covid-19",positive,positive,-0.367068694284216,neutral,-4.689998223485517,negative
2020-09-16 22:16:00.000,557.0,564.0,550.0,559.9,1097889.0,"August report: 30 stocks from large, mid & smallcap space that mutual funds bought/sold","Ashok Leyland and Minda Industries remained in the top 10 buying list of mutual funds again, while Vodafone Idea, Future Retail and Syngene International continued to be in top 10 selling list in August too.",neutral,neutral,0.5206463195691162,neutral,1.5970735189150689,positive
2020-09-24 10:31:00.000,556.95,596.7,551.0,564.9,2306631.0,"Syngene Int’l hits record high in a weak market, rallies 26% in two weeks","The stock rallied 6.5 per cent to Rs 596.85, surpassing its previous high Rs 594.75, touched on September 15, 2020, on the BSE.",positive,positive,1.4274171828709814,positive,0.6993006993006993,neutral
2020-09-24 12:04:06.000,572.0,580.55,562.6,576.0,693332.0,Advanced Enzyme Technologies Ltd leads gainers in ‘A’ group,"Apollo Hospitals Enterprise Ltd, Zydus Wellness Ltd, Bharti Infratel Ltd and Syngene International Ltd are among the other gainers in the BSEs A group today, 24 September 2020.",positive,positive,0.6993006993006993,neutral,0.3240661777247298,neutral
2020-09-24 19:44:00.000,572.0,580.55,562.6,576.0,693332.0,Syngene: Investors with long term view should look at the stock on dips,"While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger",neutral,positive,0.6993006993006993,neutral,0.3240661777247298,neutral
2020-09-29 15:17:00.000,565.6,569.7,550.05,553.0,748271.0,"COVID-19: Even as domestic demand for Remdesivir outstrips supply, manufacturers are exporting the drug","One drug company executive says as per the licensing agreement with Gilead, companies will have to cater to 127 countries. Gilead has signed deals with Cipla, Dr. Reddy’s, Hetero Labs, Jubilant Life Sciences, Mylan, Syngene and Zydus Cadila.",positive,neutral,-2.227722772277232,negative,0.7795000447988574,neutral
2020-10-01 23:22:00.000,558.05,572.95,551.65,562.4,809436.0,Syngene International joins global consortium of 19 healthcare organisations on COVID-19 testing,"A diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, the consortium will help provide clarity and potential solutions to COVID-19 testing challenges, it added.",neutral,positive,0.7795000447988574,neutral,1.7793594306049825,positive
2020-10-08 07:59:49.000,566.8,572.0,551.2,551.9,927028.0,There’s More To Syngene Stock Surge Than Remdesivir Supply Pact,"Shares of Syngene International have surged nearly threefold in the last six months, beating all benchmarks and peers.",neutral,positive,-2.6287932251234967,negative,0.3770874483749367,neutral
2020-10-08 15:48:42.000,556.9,567.8,542.05,559.0,1046278.0,Nifty Pharma index nearly doubles since March; 3 pharma stocks set to rally up to 45%,"Macquaries sees Divi’s Laboratories and Syngene International as well placed in terms of growth, margin profile and return ratios",positive,positive,0.3770874483749367,neutral,-1.4084507042253522,negative
2020-10-08 19:19:38.000,556.9,567.8,542.05,559.0,1046278.0,Biocon Foundation signs MoU with BMRCL to fund ₹65 crore in building Hebbagodi Metro Station,"Biocon Foundation, the CSR arm of Biocon Ltd, Biocon Biologics India and Syngene International Ltd have signed a Memorandum of Understanding (MoU) with the Bangalore Metro Rail Corporation Limited (BM",neutral,positive,0.3770874483749367,neutral,-1.4084507042253522,negative
2020-10-14 14:11:00.000,557.3,561.85,552.0,555.0,458146.0,Top 30 stocks that mutual funds bought and sold in September; do you own any?,"Shriram Transport Finance Company was in the top 10 buying list of MFs in August, while Syngene International and Vodafone Idea remained in the top 10 selling list in August too.",neutral,neutral,-0.4127041090974259,neutral,-0.6887914840325651,neutral
2020-10-22 02:48:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene International drops 3% post Q2 earnings; Records PAT of Rs84cr,Syngene highlighted that PAT rose by 2% during Q2FY21 if compared to Q2FY20 PAT excluding exceptional gain related to an insurance claim.,neutral,positive,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 05:47:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene Q2 net profits lower 34% at Rs84cr on a yoy basis,Syngene reported growth in top line but the bottom line faltered during the quarter.,negative,negative,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 07:59:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene International consolidated net profit declines 34.35% in the September 2020 quarter,Sales rise 11.84% to Rs 519.60 crore,negative,positive,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 09:22:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene International slips after weak Q1 performance,Syngene International fell 1.63% to Rs 543.25 after the company reported 34.3% fall in consolidated net profit to Rs 84.10 crore on 11.8% rise in net sales to Rs 519.60 crore in Q2 FY21 over Q1 FY20.,neutral,negative,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 09:22:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene International slips after weak Q2 performance,Syngene International fell 1.63% to Rs 543.25 after the company reported 34.3% fall in consolidated net profit to Rs 84.10 crore on 11.8% rise in net sales to Rs 519.60 crore in Q2 FY21 over Q2 FY20.,neutral,negative,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 11:10:28.000,553.0,553.0,514.3,532.1,1764929.0,Syngene posts 2% rise in Q2 profits at ₹84 crore,A robust operating performance during the second quarter of the current fiscal has helped Syngene International Ltd to post a 2 per cent increase in net profit to ₹84 crore on a year-on-year basis.Its,positive,positive,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 11:35:00.000,553.0,553.0,514.3,532.1,1764929.0,Syngene International drops over 5% on Q2 results,A robust operating performance during the second quarter of the current fiscal has helped Syngene International Ltd to post a 2 per cent increase in net profit to ₹84 crore on a year-on-year basis.Its,neutral,positive,-3.779385171790231,negative,-1.0185185185185186,negative
2020-10-22 14:59:37.000,540.0,540.85,530.0,534.5,986947.0,Syngene’s MD & CEO On Q2 And Remdesivir Drug Launch,Syngene’s MD & CEO On Q2 And Remdesivir Drug Launch,neutral,neutral,-1.0185185185185186,negative,2.3822513184215355,positive
2020-10-22 23:48:51.000,540.0,540.85,530.0,534.5,986947.0,"Dolat Capital: Syngene International - Operationally Weak Q2, Expect Traction In H2 FY21","Dolat Capital: Syngene International - Operationally Weak Q2, Expect Traction In H2 FY21",neutral,neutral,-1.0185185185185186,negative,2.3822513184215355,positive
2020-10-23 11:05:21.000,540.0,540.85,530.0,534.5,986947.0,"ICICI Direct: Syngene International Back On Growth Track, Outlook Maintained","ICICI Direct: Syngene International Back On Growth Track, Outlook Maintained",neutral,neutral,-1.0185185185185186,negative,2.3822513184215355,positive
2020-10-23 11:45:00.000,540.0,540.85,530.0,534.5,986947.0,Biocon stock dips ~2% after Q2FY21 profit decline,"""We have introduced ARAFLU (Favipiravir) in addition to Cytosorb and ALZUMAB-L, and Syngene has started manufacturing Remdesivir under a voluntary licensing agreement with Gilead. she added.",negative,positive,-1.0185185185185186,negative,2.3822513184215355,positive
2020-10-23 12:14:00.000,540.0,540.85,530.0,534.5,986947.0,Buy Syngene International; target of Rs 640: Dolat Capital Market,"Dolat Capital Market is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 640 in its research report dated October 22, 2020.",neutral,positive,-1.0185185185185186,negative,2.3822513184215355,positive
2020-10-25 12:03:00.000,549.9,568.75,541.15,563.0,1114879.0,Buy Syngene International; target of Rs 635: ICICI Direct,"ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 635 in its rch report dated October 23, 2020",neutral,positive,2.3822513184215355,positive,-0.3527336860670194,neutral
2020-10-27 06:00:00.000,567.0,572.8,555.1,565.0,745127.0,Broker’s call: Syngene International (Buy),"Dolat CapitalSyngene International (Buy) Target: ₹640CMP: ₹564.20Syngene reported mixed set of numbers in Q2, where the top-line growth has been healthy at 12 per cent y-o-y ($ term revenue growth – 1",neutral,negative,-0.3527336860670194,neutral,-3.619350282485876,negative
2020-10-30 18:49:19.000,540.0,553.65,529.5,533.9,290054.0,Syngene eases clients’ path to drug discovery,"Syngene International – an integrated research, development and manufacturing services company – has tasted success in drug discovery. The company has helped Albireo Pharmaceuticals in developing a cu",positive,positive,-1.129629629629634,negative,-1.483347327176051,negative
2020-11-19 05:30:00.000,573.4,573.4,565.0,568.95,286283.0,BRIEF-Syngene And Deerfield Discovery And Development Sign 5-Year Strategic Collaboration - Investing.com India,"The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.",neutral,neutral,-0.7760725497035109,neutral,0.3846153846153926,neutral
2020-11-19 20:43:00.000,572.0,575.0,562.25,574.2,572268.0,"Syngene, 3DC ink pact for advancing therapeutic discovery projects",Syngene International on Thursday said it has signed an agreement with Deerfield Discovery and Development Corporation (3DC)to collaborate for five years to advance therapeutic discovery projects.,neutral,positive,0.3846153846153926,neutral,-2.40526042567918,negative
2020-11-20 07:22:00.000,572.0,575.0,562.25,574.2,572268.0,"Stocks in the news | Reliance Industries, Tata Chemicals, Route Mobile, RPP Infra Projects, Vikas Multicorp","Gland Pharma, Mphasis, Shree Rama Newsprint, Modison Metals, Max Financial Services, Aarti Industries, UPL, Pricol, Mcdowell Holdings, Kanchi Karpooram, Autoline Industries, Himadri Speciality Chemicals, HSIL, Mahindra Holidays & Resorts, Vikas EcoTech, Syngene International, are also among the …",neutral,neutral,0.3846153846153926,neutral,-2.40526042567918,negative
2020-11-20 08:33:00.000,572.0,575.0,562.25,574.2,572268.0,"Syngene, 3DC sign 5-year strategic collaboration","Syngene International and Deerfield have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.",neutral,positive,0.3846153846153926,neutral,-2.40526042567918,negative
2020-11-20 11:23:00.000,572.0,575.0,562.25,574.2,572268.0,Syngene International collaborates with Deerfield Discovery and Development Corporation (3DC),To deliver fully integrated therapeutic discovery programs for 3DC,neutral,positive,0.3846153846153926,neutral,-2.40526042567918,negative
2020-11-20 12:50:00.000,572.0,575.0,562.25,574.2,572268.0,"Top stocks in focus: Reliance Industries, Mphasis, Tata Chemicals, Syngene International, Apollo Hospitals",Check out the stocks that will be in focus during trade today based on recent and latest news developments.,neutral,neutral,0.3846153846153926,neutral,-2.40526042567918,negative
2020-11-20 17:05:00.000,572.0,575.0,562.25,574.2,572268.0,Syngene and Deerfield Discovery enter into a 5-year strategic collaboration,"The agreement between the companies will help to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.",positive,positive,0.3846153846153926,neutral,-2.40526042567918,negative
2020-12-07 11:24:00.000,573.7,624.95,572.0,609.0,2142206.0,"Pharma shares gain; Natco, Glenmark, Syngene, Sequent Scientific up over 5%","Patient footfalls are gaining traction in healthcare units as demand from non-Covid-19 patients is gathering pace, according to a November 25 report by CARE Ratings.",positive,positive,6.153041659403861,positive,-1.5249837767683283,negative
2020-12-08 07:46:43.000,616.4,623.8,600.0,607.0,856973.0,"Trade Spotlight: Syngene, Sun Pharma, & Tata Chemicals In Focus","Stocks like Syngene International which hit a 52-week high rose more than 6 percent, Sun Pharma rose more than 2 percent, and Tata Chemicals rose more than 3 percent to hit a 52-week high were some of the stocks in focus.",neutral,positive,-1.5249837767683283,negative,-1.143186117279389,negative
2021-01-04 06:10:00.000,632.8,639.9,626.65,637.6,418409.0,Limited near term gains for Syngene International stock in pharma space,Sharp re-rating has turned the stock into the most expensive in the pharma space,positive,positive,0.7585335018963446,neutral,-0.9419152276295132,negative
2021-01-20 11:34:00.000,605.0,618.95,601.6,610.0,442502.0,Syngene Ltd Q3 PAT up 11.33% yoy at Rs102.2cr on improved revenues,Syngene Ltd reported 12.60% growth yoy in Dec-20 quarter consolidated revenues at Rs584.50cr,positive,positive,0.8264462809917356,neutral,-1.4301874595992097,negative
2021-01-21 08:09:00.000,618.8,624.0,605.05,609.95,619873.0,Syngene International consolidated net profit rises 11.33% in the December 2020 quarter,Sales rise 12.60% to Rs 584.50 crore,positive,positive,-1.4301874595992097,negative,-3.3003300330033,negative
2021-01-21 12:20:00.000,606.0,608.45,581.1,586.0,626202.0,Syngene International records 11% growth in Q3 PAT to Rs102cr; Stock gains 1%,The company’s revenue was at Rs585cr up by 13% compared to Rs519cr in the corresponding quarter of last year.,positive,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-21 12:26:00.000,606.0,608.45,581.1,586.0,626202.0,Syngene Intl Q3 PAT rises 11% YoY to Rs 102 cr,Syngene International gained 0.85% to Rs 616.6 after the drug maker posted a 11.3% rise in consolidated net profit to Rs 102.2 crore on a 12.6% rise in net sales to Rs 584.5 crore in Q3 December 2020 over Q3 December 2019.,positive,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-21 14:34:30.000,606.0,608.45,581.1,586.0,626202.0,Syngene International Q3 Profit Up 11% At Rs 102 Crore,"The company had posted a net profit of Rs 92 crore for the year-ago period, Syngene International said in a late night regulatory filing on Wednesday.",neutral,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-21 14:46:14.000,606.0,608.45,581.1,586.0,626202.0,Syngene International Q3 profit up 11 per cent at ₹102 cr,"Contract research, development and manufacturing services provider Syngene International has reported 11 per cent rise in consolidated net profit at Rs 102 crore for December quarter 2020-21.The compa",positive,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-21 15:33:52.000,606.0,608.45,581.1,586.0,626202.0,Syngene posts 11% rise in Q3 profits at ₹102 crore,"Syngene International, a Bengaluru-based integrated research, development and manufacturing services company posted 11 per cent higher profits at ₹102 crore for the third-quarter (Q3) of FY 2020-21 o",positive,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-21 15:56:00.000,606.0,608.45,581.1,586.0,626202.0,Syngene International Q3 results: Profit rises 11% to Rs 102 cr,"Revenue from the operations stood at Rs 585 crore in the quarter under review. It was Rs 519 crore in December quarter 2019-20, it added.",positive,neutral,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-22 11:04:10.000,606.0,608.45,581.1,586.0,626202.0,Syngene: A Preferred Partner Of Global Pharma Innovators; Accumulate,"Beyond contract research, another trend to watch for Syngene is the pickup in contract manufacturing business in biologics and APIs",neutral,positive,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-22 13:03:08.000,606.0,608.45,581.1,586.0,626202.0,Syngene International Q3 Review - Growth Outlook Remains Intact: Dolat Capital,Syngene International Q3 Review - Growth Outlook Remains Intact: Dolat Capital,neutral,neutral,-3.3003300330033,negative,-0.8568035290125474,neutral
2021-01-28 17:00:15.000,594.8,594.8,563.7,570.0,480146.0,Buy Syngene International; Target Of Rs 700: ICICI Direct,"ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 700 in its research report dated January 22, 2021.",neutral,positive,-4.169468728984525,negative,-1.5881326352530585,negative
2021-02-23 10:41:00.000,560.5,567.0,552.6,561.0,316390.0,"Telangana’s aiming for $100 billion life sciences exports by 2030, says Minister KT Rama Rao","Some of the companies that announced expansions and investments include Switzerland-based Ferring Pharmaceuticals, Canadian firm Jamp Pharmaceutical, Syngene, GVK Bio, Granules India, Laurus Labs and Sai Lifesciences.",neutral,neutral,0.0892060660124888,neutral,0.1773049645390071,neutral
2021-03-02 07:12:00.000,558.8,569.0,550.1,553.0,458509.0,Private equity fund True North acquires minority stake in Bengaluru-based Anthem Bio,"Set up by ex-Biocon executive Ajay Bharadwaj, Rs.1200-crore Anthem Biosciences competes with Biocon owned Syngene International and Hyderabad based GVK Bio. Outbidding global buyout funds, private equity fund True North is all set to acquire a minority stake in Anthem Biosciences, ET reported in Jan…",neutral,positive,-1.0379384395132345,negative,-0.6846846846846765,neutral
2021-04-09 19:11:00.000,562.0,571.9,553.6,558.75,577430.0,"As Covid cases rise, Zydus to scale up Remdesivir production","Companies like Cipla, Mylan, Jubilant Life Sciences, Hetero Drugs, Syngene International and Dr Reddy’s Laboratories are also manufacturing Remdesivir for the Indian market.",positive,neutral,-0.5782918149466192,neutral,-1.4157706093189923,negative
2021-04-12 21:53:13.000,550.0,572.8,549.5,565.1,329087.0,Biocon opens vaccination centre at Syngene for people in Electronic City,"Biocon Group on Monday opened Covid-19 vaccination centre at its Bengaluru campus of Syngene International Limited, as part of the nationwide drive for mass vaccination of individuals above 45 years o",neutral,neutral,2.7454545454545496,positive,0.3754147022874065,neutral
2021-04-27 13:54:19.000,599.0,617.4,591.25,610.0,640265.0,Syngene extends research collaboration with Bristol Myers Squibb,Tie up to extend through the end of 2030,positive,neutral,1.8363939899833053,positive,-6.16678918565711,negative
2021-04-28 05:30:00.000,599.0,617.4,591.25,610.0,640265.0,"Syngene targets delivering 500,000 vials of remdesivir in India in May - executive","Syngene targets delivering 500,000 vials of remdesivir in India in May - executive",neutral,neutral,1.8363939899833053,positive,-6.16678918565711,negative
2021-04-28 06:48:52.000,599.0,617.4,591.25,610.0,640265.0,Remdesivir shortfall likely to ease soon,"Remdesivir is manufactured by seven companies in India—Hetero Drugs, Zydus Cadila, Dr Reddy’s Laboratories, Cipla, Jubilant Pharma, Mylan and Syngene International—under a pact with the drug’s US-based innovator Gilead Sciences Inc",positive,neutral,1.8363939899833053,positive,-6.16678918565711,negative
2021-04-28 10:19:04.000,599.0,617.4,591.25,610.0,640265.0,Syngene’s Q4 profits up 15% at ₹138 crore,Backed by growth in discovery & manufacturing services,positive,neutral,1.8363939899833053,positive,-6.16678918565711,negative
2021-04-28 10:30:10.000,599.0,617.4,591.25,610.0,640265.0,Syngene plans $100-120 m capex for FY22,"Mangalore API facility completes qualification process, is now a GMP1-certified facility",neutral,neutral,1.8363939899833053,positive,-6.16678918565711,negative
2021-04-28 12:08:00.000,612.15,612.85,570.05,574.4,1146215.0,Syngene International allots 7.96 lakh equity shares under ESOP,"Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs. 4,00,00,00,000/- (40,00,00,000 Equity Shares of Rs. 10/- each) to Rs. 4,00,79,65,000 /- (40,07,96,500 Equity Shares of Rs. 10/- each).",neutral,neutral,-6.16678918565711,negative,-3.225806451612903,negative
2021-04-28 15:47:00.000,612.15,612.85,570.05,574.4,1146215.0,"Syngene Q4 PAT rises 15% yoy to Rs138cr, revenue increases 13% yoy",The company reports revenue from operations growth of 13% in the fourth quarter; 12% for the full year.,positive,positive,-6.16678918565711,negative,-3.225806451612903,negative
2021-04-28 15:55:00.000,612.15,612.85,570.05,574.4,1146215.0,Syngene International allots 8 lakh equity shares under RSU Plan,Syngene International allots 8 lakh equity shares under RSU Plan.,neutral,neutral,-6.16678918565711,negative,-3.225806451612903,negative
2021-04-28 20:00:01.000,612.15,612.85,570.05,574.4,1146215.0,"Syngene Targets Delivering 500,000 Vials Of Remdesivir In India As COVID-19 Surges","“At the moment we are operating at near maximum capacity (to produce remdesivir),” Chief Executive Officer Jonathan Hunt told Reuters on Wednesday.",neutral,positive,-6.16678918565711,negative,-3.225806451612903,negative
2021-04-29 09:15:00.000,612.15,612.85,570.05,574.4,1146215.0,"Discovery, development, dedicated centres and manufacturing biz contribute to Syngene growth: Jonathan Hunt",“$100-120 million capex will be for a little bit of catch-up and the rest of it will be investment in the future growth of the company.”,positive,positive,-6.16678918565711,negative,-3.225806451612903,negative
2021-04-29 12:47:03.000,573.5,574.4,551.1,555.0,1509384.0,Syngene Q4 Review - Growth Trajectory Maintained; Outlook Upbeat: ICICI Direct,Syngene Q4 Review - Growth Trajectory Maintained; Outlook Upbeat: ICICI Direct,neutral,neutral,-3.225806451612903,negative,2.391696750902527,positive
2021-04-29 15:05:04.000,573.5,574.4,551.1,555.0,1509384.0,Tejas Networks Ltd leads losers in ‘A’ group,"Panacea Biotec Ltd, Spandana Sphoorty Financial Ltd, Syngene International Ltd and Jain Irrigation Systems Ltd are among the other losers in the BSE’s ‘A’ group today, 29 April 2021.",negative,negative,-3.225806451612903,negative,2.391696750902527,positive
2021-04-30 10:55:50.000,573.5,574.4,551.1,555.0,1509384.0,Syngene: Heavy Investment Phase Makes It A Long-term Play,"Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs",neutral,positive,-3.225806451612903,negative,2.391696750902527,positive
2021-04-30 12:49:00.000,573.5,574.4,551.1,555.0,1509384.0,"Sell Syngene International, target price Rs 400: Yes Securities",Yes Securities has a sell call on Syngene International with a target price of Rs 400. The current market price of Syngene International is Rs 560.55.,neutral,positive,-3.225806451612903,negative,2.391696750902527,positive
2021-05-03 08:17:31.000,554.0,573.0,554.0,567.25,660398.0,Syngene To Spend Rs 900 Crore On Capex In FY22 As It Looks To Expand,"“Capex and opex investments are a sign of confidence in business and business model,” Jonathan Hunt, the company’s CEO, said.",neutral,positive,2.391696750902527,positive,-1.2173913043478262,negative
2021-05-26 19:50:19.000,590.0,614.4,588.45,604.4,1750504.0,Dyadic announces development of Covid vaccine in India,Dyadic said that they will develop a vaccine candidate that can protect against the emerging variants of concern.The Covid vaccine will be developed in collaboration with Syngene International,neutral,positive,2.440677966101691,positive,-1.8166666666666629,negative
2021-05-27 10:46:00.000,590.0,614.4,588.45,604.4,1750504.0,Syngene Intl gains on partnering US firm for COVID vaccine,Syngene International rose 3.27% to Rs 600.35 after the company said it has partnered US-based Dyadic International for developing COVID-19 vaccine.,positive,positive,2.440677966101691,positive,-1.8166666666666629,negative
2021-05-27 11:07:00.000,590.0,614.4,588.45,604.4,1750504.0,"Syngene targets supplying 500,000 Remdesivir vials in India amid COVID-19 surge","Syngene, majority owned by biopharmaceutical company Biocon Ltd, is one of the seven Indian companies that have licensed remdesivir from U.S.-based Gilead Sciences Inc",positive,neutral,2.440677966101691,positive,-1.8166666666666629,negative
2021-05-27 12:51:23.000,600.0,606.7,584.0,589.1,658902.0,Volumes jump at Syngene International Ltd counter,"Syngene International Ltd witnessed volume of 90869 shares by 10:49 IST on BSE, a 3.38 times surge over two-week average daily volume of 26908 shares",neutral,positive,-1.8166666666666629,negative,-1.9944458470083355,negative
2021-05-28 07:19:00.000,600.0,606.7,584.0,589.1,658902.0,"Top stocks of Osho: HDFC Life, Syngene International, L&T Info. Check why",LTI has reversed its trend from the previous swing low and is currently placed well above all its major moving averages on the daily chart,neutral,positive,-1.8166666666666629,negative,-1.9944458470083355,negative
2021-06-23 09:49:00.000,586.0,590.7,575.9,578.9,314175.0,Syngene International appoints Kush Parmar as an Additional Director,The term of appointment is till the conclusion of the 31st Annual General Meeting of the Company proposed to be held in 2024.,neutral,neutral,-1.2116040955631435,negative,0.2075047553173172,neutral
2021-07-16 09:50:24.000,700.0,700.0,646.3,663.55,6014685.0,Syngene International Ltd Surges 8.86%,Syngene International Ltd has added 14.37% over last one month compared to 4.02% gain in S&P BSE Healthcare index and 1.3% rise in the SENSEX,neutral,positive,-5.207142857142864,negative,2.8691019786910235,positive
2021-07-16 10:44:00.000,700.0,700.0,646.3,663.55,6014685.0,"Pharma shares in focus; Alkem, Divi’s Lab, Syngene hit record highs","Thus far in the financial year 2021-22 (FY22), the S&P BSE Healthcare index has rallied 24 per cent, as against 9 per cent gain in the S&P BSE Sensex",positive,positive,-5.207142857142864,negative,2.8691019786910235,positive
2021-07-16 11:04:16.000,700.0,700.0,646.3,663.55,6014685.0,Volumes spurt at Syngene International Ltd counter,"Syngene International Ltd notched up volume of 2.19 lakh shares by 10:50 IST on BSE, a 6.41 fold spurt over two-week average daily volume of 34095 shares",neutral,positive,-5.207142857142864,negative,2.8691019786910235,positive
2021-07-16 12:04:34.000,700.0,700.0,646.3,663.55,6014685.0,Sundaram Clayton Ltd leads gainers in ‘A’ group,"Nippon Life India Asset Management Ltd, Syngene International Ltd, Motilal Oswal Financial Services Ltd and PTC India Financial Services Ltd are among the other gainers in the BSE’s ‘A’ group today, 16 July 2021.",positive,neutral,-5.207142857142864,negative,2.8691019786910235,positive
2021-07-21 07:58:00.000,659.8,665.0,619.6,622.5,1175842.0,Syngene International consolidated net profit rises 33.28% in the June 2021 quarter,Sales rise 41.01% to Rs 594.50 crore,positive,positive,-5.653228250985141,negative,0.1840294447111501,neutral
2021-07-21 10:39:48.000,659.8,665.0,619.6,622.5,1175842.0,Syngene International Q1 profits up 33% yoy at ₹77.3 crore,Manufacturing of Remdesivir helped boost the profits,positive,positive,-5.653228250985141,negative,0.1840294447111501,neutral
2021-07-21 16:33:55.000,659.8,665.0,619.6,622.5,1175842.0,"Syngene Intl Consolidated June 2021 Net Sales At Rs 594.50 Crore, Up 41.01% Y-o-Y",,neutral,neutral,-5.653228250985141,negative,0.1840294447111501,neutral
2021-07-21 16:45:00.000,659.8,665.0,619.6,622.5,1175842.0,Syngene Intl Q1 PAT climbs 33% YoY to Rs 77 cr,"On a consolidated basis, Syngene International’s net profit soared 33.27% to Rs 77.30 crore on 41.01% increase in revenue from operations to Rs 594.50 crore in Q1 June 2021 (Q1 FY22) over Q1 June 2020 (Q1 FY21).",positive,positive,-5.653228250985141,negative,0.1840294447111501,neutral
2021-07-21 17:00:21.000,659.8,665.0,619.6,622.5,1175842.0,"Syngene Posts Rs 77.3 Net Profit In Q1FY22, Gets Boost From Sales Of COVID Drug Remdesivir",Revenues rose 39 percent YoY to Rs 607 crore in Q1FY22 compared to Rs 437 crore in the corresponding period of the previous year.,neutral,positive,-5.653228250985141,negative,0.1840294447111501,neutral
2021-07-22 12:19:28.000,624.9,638.0,614.45,626.05,804705.0,Remdesivir production boosted our June quarter growth strongly: Syngene CEO,"‘In FY22, we will invest in expanding our biologics plant, research facilities’",positive,positive,0.1840294447111501,neutral,0.6160000000000037,neutral
2021-07-22 17:23:00.000,624.9,638.0,614.45,626.05,804705.0,Syngene Q1 PAT increases 33% yoy to Rs77cr; Stock under pressure,"The company’s revenue from operations for the first quarter ended June 30, 2021, was up 41% yoy to Rs594.5cr.",positive,positive,0.1840294447111501,neutral,0.6160000000000037,neutral
2021-07-27 10:01:00.000,629.8,634.95,610.05,614.95,319683.0,"Margins under control, reflecting the choices we are making: Syngene MD","“Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter,” says Jonathan Hunt",neutral,positive,-2.3578913940933486,negative,2.472348731294737,positive
2021-07-27 10:01:00.000,629.8,634.95,610.05,614.95,319683.0,"Margin performance in line with expectations: Jonathan Hunt, Syngene","“Given the second wave of the pandemic that we had in India, we have seen pretty strong sales on Remdesivir: the product that we manufacture under licence from Gilead. That, of course, gave an additional boost in the quarter.”",positive,positive,-2.3578913940933486,negative,2.472348731294737,positive
2021-07-28 10:08:56.000,614.8,637.95,614.5,630.0,656603.0,Buy Syngene International; Target Of Rs 780: ICICI Direct,"ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 780 in its research report dated July 22, 2021.",neutral,positive,2.472348731294737,positive,-1.7505125374546635,negative
2021-08-27 14:33:00.000,617.9,626.5,613.65,619.0,504490.0,Select stocks gain on inclusion in F&O; Hindustan Aeronautics surges 9%,"Can Fin Homes, Polycab India, IndiaMART InterMESH, Oracle Financial Services, Syngene International, Dixon Technologies, MCX and Ipca Labs were up between 2 per cent and 3 per cent in intra-day trade.",positive,positive,0.1780223337109601,neutral,0.8503810669875579,neutral
2021-09-15 08:08:27.000,669.8,686.3,664.1,667.3,1650420.0,"Hot Stocks | Syngene International, Pidilite Industries, Sunteck Realty Can Give Up To 16% Return In Short Term","For Nifty, 17,250-17,200 zone would act as strong support with bias likely to remain in favour of bulls, said Shitij Gandhi of SMC Global Securities.",neutral,positive,-0.373245744998507,neutral,-1.4604553624925103,negative
2021-10-21 08:12:00.000,593.9,604.0,580.0,594.25,1443454.0,Syngene International stock dips 2% after Q2 PAT contracts 21% yoy due to exceptional item,"The company’s revenue stood at Rs610.2cr in the quarter under review, rising by 17% from Rs519.6cr in the corresponding period of the previous year.",positive,positive,0.0589324802155283,neutral,-2.3857868020304607,negative
2021-10-21 10:12:00.000,593.9,604.0,580.0,594.25,1443454.0,Syngene International slides after Q2 FY22 PAT tumbles 21% to Rs 67 cr,Syngene International declined 3.28% to Rs 586.55 after the company’s consolidated net profit (after exceptional items) dropped 20.68% to Rs 66.70 crore on a 17.43% surge in revenue from operations to Rs 610.20 crore in Q2 FY22 over Q1 FY21.,negative,negative,0.0589324802155283,neutral,-2.3857868020304607,negative
2021-10-21 12:22:46.000,591.0,606.7,575.0,576.9,912946.0,"Syngene Intl Standalone September 2021 Net Sales At Rs 609.50 Crore, Up 17.89% Y-o-Y",,neutral,neutral,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-21 18:52:00.000,591.0,606.7,575.0,576.9,912946.0,Syngene International consolidated net profit declines 20.69% in the September 2021 quarter,Sales rise 17.44% to Rs 610.20 crore,negative,positive,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-21 19:47:16.000,591.0,606.7,575.0,576.9,912946.0,Syngene International Q2 Net Dips 21% To Rs 67 Crore,"Revenue from operations, however, increased to Rs 610.2 crore in the second quarter as against Rs 519.6 crore in the year-ago period, Syngene International said in a regulatory filing.",neutral,positive,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-21 20:19:01.000,591.0,606.7,575.0,576.9,912946.0,Syngene International Q2 net dips 21 per cent to ₹ 67 cr,"Revenue from operations, however, increased to ₹ 610.2 crore in the second quarter",neutral,positive,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-22 01:43:33.000,591.0,606.7,575.0,576.9,912946.0,"Syngene International Q2 Review - Higher Inventory Impacts Q2, Long Term Outlook Intact: Dolat Capital","Syngene International Q2 Review - Higher Inventory Impacts Q2, Long Term Outlook Intact: Dolat Capital",neutral,neutral,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-22 11:45:05.000,591.0,606.7,575.0,576.9,912946.0,Syngene International Q2 Review - Decent Numbers Despite Some Margin Pressure: ICICI Direct,Syngene International Q2 Review - Decent Numbers Despite Some Margin Pressure: ICICI Direct,neutral,neutral,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-22 13:21:32.000,591.0,606.7,575.0,576.9,912946.0,Syngene: Look Beyond The Near-term Input Cost Pressure,"Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22",neutral,positive,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-22 16:46:17.000,591.0,606.7,575.0,576.9,912946.0,Buy Syngene International; Target Of Rs 710: ICICI Direct,"ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 710 in its research report dated October 22, 2021.",neutral,positive,-2.3857868020304607,negative,-3.2068965517241423,negative
2021-10-25 18:51:00.000,566.2,570.0,547.5,548.0,895563.0,Seeing good demand for biologics manufacturing: Syngene CEO Jonathan Hunt,"In an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of microbial and mammalian manufacturing capacities to absorb the pent up demand for biological manufacturing.",positive,positive,-3.2144118685976766,negative,-0.732435120716171,neutral
2021-10-26 12:23:16.000,552.95,563.95,546.45,548.9,909235.0,Syngene sees medium-term growth prospects intact despite some margin pressure,Key client markets in the US and Europe that are in process of returning to normal operations are helping the company’s discovery services segment,positive,neutral,-0.732435120716171,neutral,-2.072072072072072,negative
2021-10-27 12:05:00.000,555.0,557.7,538.0,543.5,1143119.0,"HDFC Life, IndiaMART: These 5 stocks can fall up to 10%. Should you sell?","Engineers India, Star Cement and Syngene International too can decline up to 7% in the medium term, indicate charts",neutral,negative,-2.072072072072072,negative,0.0184297825285703,neutral
2021-10-31 23:43:00.000,540.8,550.0,535.05,546.5,510918.0,"View: Corporate culture, world is a CEO oyster for India Inc","For India Inc, with a traditionally poor record of hiring expat CEOs, the stints of people like Paris-based Frenchman Thierry Delaporte (Wipro), Israeli national Erez Israeli (Dr Reddys Laboratories), British national Jonathan Hunt (Syngene, Biocon), American Brian Bade (Reliance Retail Digital) and…",neutral,neutral,1.0539940828402452,positive,-1.8198362147406733,negative
2021-11-16 08:20:03.000,596.9,614.75,588.95,603.6,1829812.0,"Trade Spotlight | What Should You Do With Apollo Hospitals, Syngene International, Metropolis & IRCTC Stocks?","Here’s what Mazhar Mohammad of chartviewindia.in, recommends investors should do with these stocks when the market resumes trading today.",neutral,neutral,1.122466074719391,positive,1.0604805302402611,positive
2021-11-23 15:04:12.000,587.3,596.6,575.45,577.95,502391.0,Syngene International Ltd leads losers in ‘A’ group,"Heritage Foods Ltd, Narayana Hrudayalaya Ltd, Vakrangee Ltd and IndusInd Bank Ltd are among the other losers in the BSE’s ‘A’ group today, 23 November 2021.",negative,negative,-1.5920313298143898,negative,1.767241379310345,positive
2021-12-14 08:35:00.000,626.0,632.0,602.1,608.1,1456859.0,"Buy Syngene International, target price Rs 660: Yes Securities","Syngene International Ltd., incorporated in the year 1993, is a Mid Cap company (having a market cap of Rs 24969.62 Crore) operating in Pharmaceuticals sector.",neutral,neutral,-2.859424920127792,negative,-0.2942137953579527,neutral
2021-12-16 09:50:00.000,609.45,626.5,602.2,607.3,1435330.0,Syngene International extends collaboration with Amgen until 2026,Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects.,positive,positive,-0.3527770941012537,neutral,-3.6453201970443434,negative
2021-12-16 12:25:00.000,609.0,609.0,581.55,586.8,673296.0,Syngene International gains on extending contract with Amgen Inc till 2026,"Syngene International rose 1.06% to Rs 613 after the company announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc, a US-based biotechnology firm till 2026.",positive,positive,-3.6453201970443434,negative,-1.0932695592757051,negative
2021-12-16 14:08:00.000,609.0,609.0,581.55,586.8,673296.0,Syngene International extends collaboration with Amgen Inc.,"The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug",positive,neutral,-3.6453201970443434,negative,-1.0932695592757051,negative
2022-01-19 07:54:00.000,606.3,607.0,588.45,595.0,492126.0,"Stocks in the news: Bajaj Auto, Hero Moto, NTPC, Dixon, LTTS and ICICI Pru","Bajaj Auto, L&T Info, ICICI Lombard, JSW Energy, Tata Communications, OFFS, Syngene International, Sterlite Techn, Saregama and Mastek are among the companies that will announce their December quarter results today.",neutral,neutral,-1.8637638132937413,negative,1.033247229397558,positive
2022-01-20 11:11:23.000,600.05,629.45,595.3,606.25,2338698.0,"Syngene Intl Consolidated December 2021 Net Sales At Rs 641.40 Crore, Up 9.73% Y-o-Y",,neutral,neutral,1.033247229397558,positive,-2.04769736842106,negative
2022-01-20 11:11:51.000,600.05,629.45,595.3,606.25,2338698.0,"Syngene Intl Standalone December 2021 Net Sales At Rs 639.50 Crore, Up 9.48% Y-o-Y",,neutral,neutral,1.033247229397558,positive,-2.04769736842106,negative
2022-01-20 13:16:00.000,608.0,610.6,591.0,595.55,491093.0,Syngene International gains after decent Q3 earnings,Syngene International rose 1.51% to Rs 603.20 after the company’s consolidated net profit rose 2% to Rs 104 crore on a 10% rise in revenue from operations to Rs 641.4 crore in Q3 FY22 over Q3 FY21.,positive,positive,-2.04769736842106,negative,-2.6936026936026933,negative
2022-01-20 13:24:21.000,608.0,610.6,591.0,595.55,491093.0,Syngene posts 10% growth in operational revenue in Q3,Company’s PAT was up 2% at ₹104 crore,positive,positive,-2.04769736842106,negative,-2.6936026936026933,negative
2022-01-20 18:14:00.000,608.0,610.6,591.0,595.55,491093.0,Manufacturing segment will grow fast over the next decade: Syngene CEO,"In a Q&A, Jonathan Hunt talks about his company’s capex plans and strategic initiatives going forward",positive,neutral,-2.04769736842106,negative,-2.6936026936026933,negative
2022-01-21 09:49:28.000,608.0,610.6,591.0,595.55,491093.0,"Syngene Intl Standalone December 2021 Net Sales At Rs 639.50 Crore, Up 9.48% Y-o-Y",,neutral,neutral,-2.04769736842106,negative,-2.6936026936026933,negative
2022-01-21 12:38:14.000,608.0,610.6,591.0,595.55,491093.0,"Syngene International Q3 Review - Guidance Raised On Upbeat Numbers, Outlook: ICICI Direct","Syngene International Q3 Review - Guidance Raised On Upbeat Numbers, Outlook: ICICI Direct",neutral,neutral,-2.04769736842106,negative,-2.6936026936026933,negative
2022-01-23 15:41:50.000,594.0,594.0,566.05,578.0,530170.0,Syngene International looks to carry growth momentum to next fiscal,Syngene International looks to carry growth momentum to next fiscal,positive,positive,-2.6936026936026933,negative,0.3580160670625139,neutral
2022-01-31 14:01:18.000,579.0,580.0,569.15,578.25,240446.0,Buy Syngene International; Target Of Rs 710: ICICI Direct,"ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 710 in its research report dated January 21, 2022.",neutral,positive,-0.1295336787564767,neutral,0.6094943771997519,neutral
2022-03-02 09:23:41.000,541.75,546.75,533.65,537.9,321815.0,Stocks that will see action on March 2,"Buzzing stocks: Reliance Ind, automobile cos, L&T Finance Holdings, Vipul Organics, Prestige Estates, Bharat Forge, Syngene International, Lupin, Lemon Tree, Route Mobile, Quint Digital, Infibeam Avenues, IIFL Asset",neutral,neutral,-0.7106598984771615,neutral,-1.4654698662758747,negative
2022-03-11 08:50:00.000,560.0,581.0,557.45,579.5,432921.0,CRISIL places AA+ rating on the long-term bank facilities of Syngene on ‘Watch with Developing Implications’,The rating on the short-term bank facilities has been reaffirmed at ‘CRISIL A1+’.,neutral,positive,3.482142857142857,positive,-1.8128705215224792,negative
2022-04-19 21:55:37.000,610.0,630.75,609.95,630.5,187571.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, a long unwinding was seen in 112 stocks including Jubilant Foodworks, Pfizer, Tata Power, Alkem Laboratories, and Syngene International.",neutral,positive,3.360655737704918,positive,0.0796876245119133,neutral
2022-04-27 15:10:00.000,615.0,632.8,596.45,622.1,1141143.0,Syngene International Q4 FY22 PAT slips 8% YoY to Rs 148 cr,Syngene International’s consolidated net profit fell 7.97% to Rs 147.80 crore on a 15.10% rise in revenue from operations to Rs 758.10 crore in Q4 FY22 over Q4 FY21.,neutral,negative,1.1544715447154508,positive,-0.0718333466358121,neutral
2022-04-27 16:06:00.000,615.0,632.8,596.45,622.1,1141143.0,Syngene International consolidated net profit declines 7.97% in the March 2022 quarter,Sales rise 15.11% to Rs 758.10 crore,negative,positive,1.1544715447154508,positive,-0.0718333466358121,neutral
2022-04-27 20:25:00.000,615.0,632.8,596.45,622.1,1141143.0,Syngene’s Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr,The company had reported a PAT of Rs 138 crore in the January-March period of 2020-21,positive,neutral,1.1544715447154508,positive,-0.0718333466358121,neutral
2022-04-28 08:42:58.000,615.0,632.8,596.45,622.1,1141143.0,"Syngene Intl Consolidated March 2022 Net Sales at Rs 758.10 crore, up 15.11% Y-o-Y",,positive,neutral,1.1544715447154508,positive,-0.0718333466358121,neutral
2022-06-15 21:08:30.000,564.0,568.7,533.7,536.9,544953.0,Trade setup for Thursday: Top 15 things to know before Opening Bell,"Based on the open interest future percentage, short-covering was seen in 78 stocks including Deepak Nitrite, Syngene International, Polycab India, Ashok Leyland, and Shriram Transport Finance",neutral,neutral,-4.804964539007097,negative,0.0,neutral
2022-07-06 14:29:04.000,547.3,575.0,547.3,574.65,322685.0,Biocon arm Syngene ends contract with Bioinnovat Research over graft case,Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive,neutral,neutral,4.99725927279372,positive,0.6770833333333294,neutral
2022-07-14 19:04:04.000,604.9,617.0,591.1,614.15,3049722.0,Syngene International signs 10-year deal with Zoetis,"Syngene’s collaboration with Zoetis started in 2011. Over the past 11 years, Syngene has undertaken development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of a treatment",neutral,neutral,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 01:16:20.000,604.9,617.0,591.1,614.15,3049722.0,"Syngene International, Zoetis To Manufacture Drug Treating Osteoarthritis In Dogs",Syngene International signed a 10-year agreement with animal health company Zoetis to manufacture the drug substance for Librela which is used for treating osteoarthritis in dogs.,neutral,positive,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 01:51:42.000,604.9,617.0,591.1,614.15,3049722.0,Syngene International signs 10-year agreement with US-based firm Zoetis,"Librela or bedinvetmab has already been launched in Europe and the UK, and has won ‘Best new companion animal product’ by IHS Markit Connect in 2021",positive,positive,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 05:30:00.000,604.9,617.0,591.1,614.15,3049722.0,"Mega & Large-Cap Stocks in Focus: LIC, Bharti Airtel, Syngene, Jindal Steel & More","Mega & Large-Cap Stocks in Focus: LIC, Bharti Airtel, Syngene, Jindal Steel & More",neutral,neutral,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 07:34:00.000,604.9,617.0,591.1,614.15,3049722.0,Syngene stock zooms over 4% on signing 10-year biologics manufacturing agreement with Zoetis,"This agreement, initially centred on Librela, paves the way for development and manufacturing of other molecules in the coming years.",neutral,positive,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 08:57:42.000,604.9,617.0,591.1,614.15,3049722.0,"Stocks that will see action on July 15, 2022","Buzzing stocks: L&T Technologies, LIC, Cipla, Syngene International, AB Money, Federal Bank, Mahindra Holidays, Mukand, SecureKloud Tech, Kesoram, Oberoi Realty",neutral,neutral,1.5291783765911722,positive,1.620125376536684,positive
2022-07-15 09:20:11.000,604.9,617.0,591.1,614.15,3049722.0,Syngene inks 10-year biologics manufacturing pact with Zoetis,The agreement is expected to be worth up to $500 million over 10 years,positive,neutral,1.5291783765911722,positive,1.620125376536684,positive
2022-07-17 19:21:33.000,614.15,627.15,614.15,624.1,611700.0,Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In’l chief,"In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm’s initiatives to overcome supply chain bottlenecks and other issues",neutral,neutral,1.620125376536684,positive,-0.0567674965533872,neutral
2022-07-19 16:35:00.000,619.8,620.0,593.6,603.4,1196495.0,CRAMs: CRAMs a huge IT-like opportunity for India and other Asian countries: Pankaj Muraka,"“A few days back, Syngene had the first long-term deal with a big global pharma company, a $500-million deal over a period of 10 years which is very significant in the contract manufacturing space and it essentially shows the potential for Indian contract manufacturers in the CRAMS space.”",positive,neutral,-2.646014843497899,negative,0.2841383921109887,neutral
2022-07-20 07:46:31.000,619.8,620.0,593.6,603.4,1196495.0,"Stocks to Watch: RIL, HUL, ONGC, NTPC, Ambuja, HDFC Life, Grasim, Vedanta","Stocks to Watch Today: CEAT, Havells, IndusInd Bank, Mastek, OFSS, RIIL, Syngene International, Tata Communications and Wirpo to announce Q1 results on Wednesday.",neutral,neutral,-2.646014843497899,negative,0.2841383921109887,neutral
2022-07-20 08:34:00.000,619.8,620.0,593.6,603.4,1196495.0,"Corporate Radar: Orient Cement to turn ex-dividend; Wipro Q1 results; ITC AGM, and more","Wipro, Havells India, IndusInd Bank, Gland Pharma, Tata Communications, Oracle Financial Services Software, Syngene International, Mastek, Ceat and Hathway Cable are among the companies that will announce their quarterly earnings today.",neutral,neutral,-2.646014843497899,negative,0.2841383921109887,neutral
2022-07-20 14:31:15.000,598.3,605.0,589.6,600.0,611884.0,Syngene International slips after muted Q1 performance,Syngene International fell 3.03% to Rs 596 after the company’s consolidated net profit declined 4.4% to Rs 73.9 crore in Q1 FY23 from Rs 77.3 crore in Q1 FY22.,positive,negative,0.2841383921109887,neutral,-5.241264559068219,negative
2022-07-20 19:42:59.000,598.3,605.0,589.6,600.0,611884.0,Syngene raises full-year revenue guidance despite dip in PAT by 4% in Q1,"The decline in profit was as expected given the strong sales of Remdesivir last year, said MD and CEO",positive,negative,0.2841383921109887,neutral,-5.241264559068219,negative
2022-07-20 22:08:30.000,598.3,605.0,589.6,600.0,611884.0,Syngene International Q1 PAT slips 4% to Rs 74 cr; revenue rises 8%,Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022.,positive,negative,0.2841383921109887,neutral,-5.241264559068219,negative
2022-07-21 14:24:00.000,601.0,606.0,568.0,569.5,1090107.0,Jonathan Hunt on growth triggers which led to upgrade of Syngene sales guidance,“ Syngene has signed a 10-year strategic deal with Zoetis in animal health: It was a real piece of innovation from Zoetis and we are delighted to sign the deal which is a strategic one and is in the biologics manufacturing part of the organisation. They should get going with that set up starting thi…,positive,positive,-5.241264559068219,negative,-1.3054830287206265,negative
2022-07-21 14:33:54.000,601.0,606.0,568.0,569.5,1090107.0,Q1 Review | Syngene’s MD & CEO Shares Outlook For FY23,Q1 Review | Syngene’s MD & CEO Shares Outlook For FY23 #Q1WithBQ | Syngene reports an 8% jump in revenue even as net profit contracts by 8%.CEO Jonathan Hunt shares his view on quarter gone by and projections for the rest of FY23.,neutral,positive,-5.241264559068219,negative,-1.3054830287206265,negative
2022-07-24 12:40:29.000,574.5,579.85,566.1,567.0,514460.0,Syngene International Q1 Review - Order Win Vindicates Capabilities; Execution To Be The Key: ICICI Direct,Syngene International Q1 Review - Order Win Vindicates Capabilities; Execution To Be The Key: ICICI Direct,neutral,neutral,-1.3054830287206265,negative,-0.1573701696100677,neutral
2022-07-27 22:17:09.000,578.7,579.0,562.2,571.65,1128212.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 103 stocks including IndiaMART InterMESH, Astral, Gujarat State Petronet, Syngene International, and Dalmia Bharat, in which short-covering was seen.",neutral,neutral,-1.218247796785911,negative,-1.798374546083344,negative
2022-08-23 22:09:20.000,593.05,617.8,591.15,612.0,1286045.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 85 stocks including Syngene International, Voltas, Tata Chemicals, Polycab India, and Indus Towers, in which short-covering was seen.",neutral,neutral,3.195346092235064,positive,-2.6158082280531225,negative
2022-08-29 01:00:00.000,600.0,612.4,594.0,604.3,451401.0,"Stocks To Watch Today: Cipla, Reliance Industries, RITES, Syngene, UltraTech Cement",Stocks to watch before going into trade today.,neutral,neutral,0.7166666666666591,neutral,-0.3305785123966942,neutral
2022-08-29 08:30:46.000,600.0,612.4,594.0,604.3,451401.0,"Stocks that will see action on August 29, 2022","Buzzing stocks: Reliance, Tata Steel, Glenmark Pharma, Cipla, Aster DM Healthcare, Syngene, UltraTech Cement, Adani Total, GMR Power, RITES, NHPC, Jubilant Pharmova",neutral,neutral,0.7166666666666591,neutral,-0.3305785123966942,neutral
2022-09-01 14:30:00.000,599.35,615.5,590.05,592.0,454542.0,"Syngene to benefit from rupee depreciation, rising demand for research & manufacturing services: CEO Jonathan Hunt",Syngene has raised the revenue guidance for FY23 from mid-teens to high teens due to significant depreciation of rupee against the dollar and signing up new contracts. Rupee depreciated almost 5% since April 1 against the dollar.,positive,positive,-1.2263285225661171,negative,-2.080162354134949,negative
2022-09-06 10:31:38.000,562.0,599.3,559.5,565.75,6978041.0,Syngene trades weak after nearly 6% equity changes hands via block deals,"At 09:15 am; around 22.68 million equity shares representing 5.65 per cent of the total equity of Syngene changed hands on the BSE, the exchange data shows.",negative,neutral,0.6672597864768683,neutral,0.9646871404548952,positive
2022-09-06 15:05:46.000,564.95,573.0,562.7,570.4,632797.0,Volumes spurt at Syngene International Ltd counter,"Syngene International Ltd registered volume of 67.86 lakh shares by 14:14 IST on NSE, a 12.78 fold spurt over two-week average daily volume of 5.31 lakh shares",neutral,positive,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-06 20:14:42.000,564.95,573.0,562.7,570.4,632797.0,Biocon sells 5.4% stake in its research arm Syngene International,"According to bulk deal data available with the BSE, Biocon, the promoter of Syngene International, sold a total of 21,789,164 shares, amounting to a 5.4 per cent stake, in the company.",neutral,neutral,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-06 21:11:03.000,564.95,573.0,562.7,570.4,632797.0,"Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal","While the promoter offloaded a portion of its shares in Syngene, ICICI Prudential Mutual Fund, on the other hand, bought shares worth over ₹158 crore.",neutral,neutral,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-06 22:21:34.000,564.95,573.0,562.7,570.4,632797.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 66 stocks including Syngene International, HDFC AMC, Oracle Financial, Bharat Electronics, and Torrent Pharma, in which a short build-up was seen.",neutral,neutral,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-06 23:38:30.000,564.95,573.0,562.7,570.4,632797.0,"Biocon sells 5.4% stake in arm Syngene International for Rs 1,220 cr","Drugmaker Biocon divested a 5.4% stake in its research arm Syngene International for a little over Rs 1,220 crore through an open market transaction",neutral,neutral,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-07 07:16:00.000,564.95,573.0,562.7,570.4,632797.0,"Stocks in the news: Wipro, IndiGo, Astral, Paras Defence and Syngene","The budget carrier IndiGo has said Pieter Elbers, who was named as the Chief Executive Officer of the company to replace Ronojoy Dautta, has joined the position.",neutral,neutral,0.9646871404548952,positive,-0.5449826989619337,neutral
2022-09-28 21:10:54.000,551.0,559.65,545.7,555.0,477995.0,Trade setup for Thursday: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 97 stocks including City Union Bank, IndiaMART InterMESH, Syngene International, Navin Fluorine International, and Atul, in which long unwinding was seen.",neutral,neutral,0.7259528130671506,neutral,1.7294458529518206,positive
2022-09-29 21:45:22.000,552.2,562.0,551.9,561.75,166507.0,Trade setup for Friday: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 108 stocks, in which short-covering was seen including Syngene International, Alkem Laboratories, City Union Bank, Shree Cement, and Escorts.",neutral,neutral,1.7294458529518206,positive,-0.2226378128061269,neutral
2022-09-30 17:30:00.000,552.2,562.0,551.9,561.75,166507.0,Biocon’s subsidiary Syngene’s shares drop 12% in 2022; here’s what management and analysts have to say,Kiran Mazumdar’s contract research and manufacturing firm Syngene International has been on a roller coaster ride on Dalal Street in the ongoing calendar year.,negative,neutral,1.7294458529518206,positive,-0.2226378128061269,neutral
2022-10-12 00:07:00.000,564.9,565.45,553.15,554.2,496404.0,Syngene set for phase-2 trial of Covid oral tablet vaccine,Vaxart had started trials of its oral recombinant tablet vaccine in October last year. It enrolled 96 participants at four centres in the US. Participants included both-the untreated as well as previously vaccinated subjects.,neutral,neutral,-1.8941405558505808,negative,-0.4623334239869376,neutral
2022-10-17 21:30:07.000,538.2,557.3,535.1,552.45,516440.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 48 stocks in which a short build-up was seen, including Syngene International, Shree Cement, Can Fin Homes, Persistent Systems, and NALCO",neutral,neutral,2.6477146042363437,positive,7.246904588492343,positive
2022-10-19 15:16:10.000,577.5,600.0,575.15,582.0,1079755.0,Syngene Intl soars after Q2 PAT rises 53% YoY; EBITDA margins remain stable,Syngene International jumped 7.66% to Rs 596.90 after the company reported 53% rise in consolidated net profit to Rs 102 crore on a 26% rise in revenue from operations to Rs 768 crore in Q2 FY23 over Q2 FY22.,positive,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-19 16:26:47.000,577.5,600.0,575.15,582.0,1079755.0,Syngene International gains over 6% on September quarter earnings,"Syngene International, the research subsidiary of Biocon, has reported a 53 percent year-on-year growth in consolidated profit at Rs 102 crore in the September quarter",positive,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-19 16:31:23.000,577.5,600.0,575.15,582.0,1079755.0,Syngene International consolidated net profit rises 52.92% in the September 2022 quarter,Sales rise 25.88% to Rs 768.10 crore,positive,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-19 19:23:32.000,577.5,600.0,575.15,582.0,1079755.0,Syngene International’s net profit rises 53% to Rs 102 crore in Q2,Syngene International on Wednesday reported a 53 per cent rise in consolidated net profit at Rs 102 crore in the second quarter ended September 2022 on the back of higher revenue,positive,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-19 20:51:00.000,577.5,600.0,575.15,582.0,1079755.0,Syngene reports Rs 102 crore net profit in Q2FY23,"The company reported net profit of Rs 102 crore during Q2FY23, compared to Rs 67 crore during the corresponding quarter of the previous year. Revenues rose 26% YoY to Rs 784 crore in Q2FY23 compared to Rs 623 in the year ago period.",neutral,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-20 07:33:00.000,577.5,600.0,575.15,582.0,1079755.0,Syngene International’s Q2 net profit increased by 53% to Rs 102 crore,"On the strength of stronger revenue, Syngene International on Wednesday reported a 53% increase in its combined net profit for the second quarter ended September 2022, coming in at Rs102 crore",positive,positive,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-20 09:58:52.000,577.5,600.0,575.15,582.0,1079755.0,"Syngene: Can it keep its premium valuation, going forward?",Investment in biologics is expected to remain recurring as new opportunities are unfolding in the field of biologics for Syngene,positive,neutral,0.7792207792207793,neutral,-0.4381443298968994,neutral
2022-10-21 12:46:30.000,582.0,595.05,575.15,579.45,377814.0,Q2 Review: Syngene International Beats Estimates,Q2 Review: Syngene International Beats Estimates Syngene International reports better than expected numbers as the consolidated profit jumps over 50% year-on-year.MD & CEO Jonathan Hunt speaks about the company’s performance and growth targets in coming quarters.,neutral,positive,-0.4381443298968994,neutral,-1.0309278350515465,negative
2022-10-24 12:46:56.000,577.45,592.5,575.05,585.95,365078.0,Buy Syngene International; target of Rs 710: ICICI Direct,"ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 710 in its research report dated October 21, 2022.",neutral,positive,1.4719889167893323,positive,0.9345794392523364,positive
2023-01-05 22:13:58.000,593.0,603.25,592.2,596.25,383943.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the OI percentage, a total of 75 stocks witnessed short-covering on Thursday, including Cummins India, Syngene International, Gujarat Gas, GAIL India, and Britannia Industries.",neutral,neutral,0.5480607082630692,neutral,-0.334448160535117,neutral
2023-01-11 10:36:30.000,616.0,626.55,611.55,623.0,713567.0,"Jefferies sees big pharma firms getting bigger, lists Sun Pharma, Syngene as top picks",The USD 27 billion domestic pharma industry has structural growth drivers in place and well-placed to achieve low double-digit growth in the coming years.,positive,positive,1.1363636363636365,positive,-1.5465982851190143,negative
2023-01-23 17:30:00.000,603.0,606.9,577.2,578.0,600516.0,"Stocks in news: Yes Bank, RIL, JSW Steel, UltraTech Cement, SBI and other banks","Axis Bank, IDBI Bank, Canara Bank, Container Corporation of India, Tata Communications, Syngene, Gland Pharma, Poonawalla Fincorp, KEI Industries, Jindal Stainless and HFCL are among the companies that will announce their results for the December 2022 quarter.",neutral,neutral,-4.1459369817578775,negative,-1.472741365946078,negative
2023-01-23 22:44:39.000,603.0,606.9,577.2,578.0,600516.0,"Syngene Intl Standalone December 2022 Net Sales at Rs 786.60 crore, up 23% Y-o-Y",,positive,neutral,-4.1459369817578775,negative,-1.472741365946078,negative
2023-01-24 09:05:36.000,603.0,606.9,577.2,578.0,600516.0,Syngene International consolidated net profit rises 5.48% in the December 2022 quarter,Sales rise 22.53% to Rs 785.90 crore,positive,positive,-4.1459369817578775,negative,-1.472741365946078,negative
2023-01-24 11:04:05.000,603.0,606.9,577.2,578.0,600516.0,Syngene International records PAT of Rs 110 cr in Q3 FY23,Syngene International reported a 5.5% rise in consolidated net profit to Rs 109.70 crore in Q3 FY23 as against Rs 104 crore posted in Q3 FY22.,neutral,positive,-4.1459369817578775,negative,-1.472741365946078,negative
2023-01-24 11:16:53.000,603.0,606.9,577.2,578.0,600516.0,Syngene net profit up 5.9 per cent to ₹109.5 crore,"During this quarter, the earnings per share increased to ₹2.73 compared to ₹2.55 in the same quarter last year.",positive,positive,-4.1459369817578775,negative,-1.472741365946078,negative
2023-01-24 14:35:15.000,580.55,581.35,570.0,572.0,417139.0,Q3 Review | Syngene International’s Growth Strategies & Projections For 2023,"Q3 Review | Syngene International’s Growth Strategies & Projections For 2023 #Q3WithBQ | Syngene international reports in-line set of earnings, even as revenues see strong growth in Q3.MD & CEO Jonathan Hunt shares projections for Q4 & beyond.",neutral,positive,-1.472741365946078,negative,-1.7220386154113718,negative
2023-01-25 13:08:29.000,580.55,581.35,570.0,572.0,417139.0,Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch,Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.,neutral,neutral,-1.472741365946078,negative,-1.7220386154113718,negative
2023-02-01 09:00:24.000,572.9,583.4,563.25,565.8,2433031.0,"Stocks that will see action on February 1, 2023","Buzzing stocks: Automobile companies Reliance Industries, Tata Motors, Biocon, Syngene International, VOdafone Idea, Ajanta Pharma, Alembic Pharma, Ashok Leyland, Britannia, Gillette, Hindustan Copper, IDFC, Jubilant Foodworks, Kaya, LMW, Mahindra Logistics, Ramco Systems, Raymond, Redington, RPG L…",neutral,neutral,-1.2393087798917826,negative,-1.3019000703729728,negative
2023-02-01 09:39:22.000,572.9,583.4,563.25,565.8,2433031.0,"Syngene International sees 4 crore shares sold in block deal, Biocon likely seller","As of December end, Biocon held 64.5 percent promoter stake in Syngene International. After the block deal, this will go down to 54.5 percent.",neutral,neutral,-1.2393087798917826,negative,-1.3019000703729728,negative
2023-02-01 11:04:05.000,572.9,583.4,563.25,565.8,2433031.0,Volumes soar at Syngene International Ltd counter,"Syngene International Ltd clocked volume of 400.54 lakh shares by 10:47 IST on BSE, a 2450.39 times surge over two-week average daily volume of 16346 shares",neutral,positive,-1.2393087798917826,negative,-1.3019000703729728,negative
2023-02-01 19:33:39.000,568.4,573.5,560.05,561.0,669483.0,Biocon sells 9.96% stake in contract research firm Syngene via open market,"Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing",neutral,neutral,-1.3019000703729728,negative,1.6041351038231888,positive
2023-02-02 07:16:58.000,568.4,573.5,560.05,561.0,669483.0,"Stocks to Watch: Adani Enterprises, Britannia, Maruti, Syngene, LIC, TVS","HDFC, Titan, Tata Consumer, Dabur India, Zydus, Berger Paints, Max Healthcare, Apollo Tyres, and Bajaj Electricals will be among the stocks in focus as they declare their December quarter earnings today.",neutral,neutral,-1.3019000703729728,negative,1.6041351038231888,positive
2023-02-07 22:43:05.000,547.5,563.35,545.0,560.0,1422728.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the OI percentage, a short build-up was seen in 71 stocks including Syngene International, LIC Housing Finance, Deepak Nitrite, Escorts, and InterGlobe Aviation",neutral,positive,2.28310502283105,positive,2.787769784172662,positive
2023-02-23 22:52:31.000,584.75,586.75,563.85,566.25,464367.0,Trade setup for Friday: Top 15 things to know before the opening bell,"Based on the OI percentage, as many as 17 stocks were on the short-covering list. These included Coforge, United Breweries, ONGC, InterGlobe Aviation, and Syngene International",neutral,neutral,-3.163745190252244,negative,0.6620178303468973,neutral
2023-04-26 20:52:05.000,644.6,660.0,632.0,649.0,3769111.0,Syngene International’s PAT rises 21% at Rs 179 cr in March quarter,Contract manufacturing services firm Syngene International on Wednesday said its profit after tax rose 21 per cent to Rs 179 crore during the March quarter.,positive,positive,0.6825938566552866,neutral,2.992366412213744,positive
2023-04-27 09:05:04.000,644.6,660.0,632.0,649.0,3769111.0,Syngene’s net income rises by 31% to ₹994 crore in Q4FY23,Syngene International’s PAT was up by 21 per cent YoY to ₹178 crore compared to ₹147 crore in Q4 FY22.,positive,positive,0.6825938566552866,neutral,2.992366412213744,positive
2023-04-27 10:17:32.000,644.6,660.0,632.0,649.0,3769111.0,Syngene International scales 52-week high on 21% rise in Q4 net profit,Syngene International delivered the highest absolute year-on-year increase in revenue and EBITDA in the last 5 years in FY23.,positive,positive,0.6825938566552866,neutral,2.992366412213744,positive
2023-04-27 16:42:35.000,655.0,685.7,653.0,674.6,2785702.0,Syngene’s MD & CEO On Q4 Report Card & FY24 Focus Areas,Syngene’s MD & CEO On Q4 Report Card & FY24 Focus Areas Good growth momentum on R&D and manufacturing helps Syngene fuel ‘better than expected’ Q4 earnings. MD & CEO Jonathan Hunt shares projections for FY24.,neutral,positive,2.992366412213744,positive,2.390085570964893,positive
2023-04-28 13:02:31.000,655.0,685.7,653.0,674.6,2785702.0,Buy Syngene International; target of Rs 740: ICICI Direct,"ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 740 in its research report dated April 27, 2023.",neutral,positive,2.992366412213744,positive,2.390085570964893,positive
2023-05-01 20:29:56.000,677.8,699.5,677.8,694.0,1885914.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the OI percentage, 83 stocks, including Aarti Industries, Syngene International, IndiaMART InterMESH, Laurus Labs, and IDFC First Bank, saw long build-ups.",neutral,positive,2.390085570964893,positive,-0.6067610517191628,neutral
2023-05-02 08:56:00.000,677.8,699.5,677.8,694.0,1885914.0,"Big Movers on D-St: What should investors do with Syngene International, REC and EIH?","Sectorally, buying was seen in telecom, capital goods, utilities, public sector and power stocks while selling was seen in consumer durables. Stocks that were in focus include names like Syngene International which rose more than 4%, EIH rallied nearly 10% and REC closed with gains of over 5% on Fri…",neutral,positive,2.390085570964893,positive,-0.6067610517191628,neutral
2023-05-02 17:30:00.000,692.2,706.2,686.25,688.0,1035092.0,"HAL, Syngene, Hindustan Oil & OFSS: Axis Securities sees up to 21% rise in these stocks","HAL on the weekly chart has decisively broken out above the ‘cup and handle’ pattern above Rs 2,880 level. The breakout is accompanied by an increase in volume confirming participation at the breakout level.",positive,neutral,-0.6067610517191628,neutral,0.2031930333817093,neutral
2023-05-05 13:49:00.000,691.5,706.0,688.05,695.1,1140504.0,CRO Market | JM Financial Stocks: CRO market still very much untapped in India: Cyndrella Carvalho,"Indian CROs and CDMOs are attracting a lot of attention as companies, such as Syngene, Suven, and Divis, create long-term relationships with top pharma organisations. According to Cyndrella Carvalho of JM Financial, India still has a vital untapped CRO market, and with its large and diverse populati…",neutral,positive,0.520607375271153,neutral,0.1866743251005267,neutral
2023-05-09 00:24:00.000,700.0,712.0,698.6,701.0,1052484.0,Syngene International sees strong momentum this fiscal year: MD,Syngene International also expects business growth from its pharma clients who are keen to make up for the time that they felt they lost during the Covid-19 pandemic.,positive,positive,0.1428571428571428,neutral,-0.1991465149359854,neutral
2023-05-11 22:47:22.000,709.5,718.9,697.85,700.85,702603.0,Trade setup for Friday: Top 15 things to know before the opening bell,"Based on the OI percentage, 60 stocks were on the short-covering list. These included Oracle Financial, GNFC, Syngene International, Aarti Industries, and Pidilite Industries.",neutral,neutral,-1.219168428470751,negative,-0.0857694232006159,neutral
2023-06-07 10:25:36.000,740.95,746.75,730.05,732.8,530018.0,BSE Smallcap index hits record high; experts see more upside,"Aurionpro, BDL, Centum Electronics, Cigniti Techno, Data Patterns, Dreamfolks, Fusion Micro, IOX Exchange, KDDL, Mahindra CIE, Safari Ind and Syngene hit their respective all-time highs today",positive,neutral,-1.0999392671570405,negative,-1.3024207296283608,negative
2023-07-05 01:06:00.000,750.95,760.7,740.35,754.9,692454.0,Strides sells arm’s manufacturing unit to Syngene International for Rs 702 crore,Strides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene International for INR702 crore ($94m) in cash. Syngene will also invest up to INR100 crore to repurpose and revalidate the Bommasandra Industrial Area in Bengalu…,neutral,neutral,0.5260003994939652,neutral,1.014626432995131,positive
2023-07-05 05:00:00.000,750.95,760.7,740.35,754.9,692454.0,"Stocks To Watch: LTIMindtree, Samvardhana Motherson, Jindal Steel, Mankind Pharma, SBI, Ambuja, Syngene",Here are the stocks to watch before going into trade.,neutral,neutral,0.5260003994939652,neutral,1.014626432995131,positive
2023-07-05 08:58:50.000,750.95,760.7,740.35,754.9,692454.0,Stocks that will see action today (July 5),"Stocks likely to see action on July 5 are PSU banks, BHEL, LTIMindtree, Aurobindo Pharma, Genus Power, Lodha, Samvardhana Motherson, IOC, Suzlon, Strides Pharma, Syngene International, Bandhan Bank",neutral,neutral,0.5260003994939652,neutral,1.014626432995131,positive
2023-07-05 10:07:43.000,750.95,760.7,740.35,754.9,692454.0,Syngene to acquire plant from Stelis Biopharma for Rs 702 crore,"The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.",neutral,positive,0.5260003994939652,neutral,1.014626432995131,positive
2023-07-05 10:36:33.000,750.95,760.7,740.35,754.9,692454.0,Syngene to acquire Unit 3 biologics manufacturing site for gross value of ₹702 cr,Syngene will acquire a Unit 3 biologics manufacturing facility in Bengaluru from Stelis Biopharma Limited (SBL) on a slump sale basis for a gross value of ₹702 crore. The facility is being repurposed to manufacture monoclonal antibodies; Syngene to further invest up to ₹100 crore to repurpose and re…,neutral,neutral,0.5260003994939652,neutral,1.014626432995131,positive
2023-07-05 20:31:43.000,758.9,769.9,751.5,766.6,546363.0,Syngene acquires facility from Stelis Biopharma for ₹ 702 cr,"Syngene International, a subsidiary of Biocon Ltd., has decided to acquire a Unit 3 biologics manufacturing facility in Bengaluru from Stelis Biopharma Limited (SBL) on a slump sale basis for a gross value of ₹702 crore.",neutral,neutral,1.014626432995131,positive,-0.5156994581891827,neutral
2023-07-26 18:28:14.000,780.95,813.0,766.85,810.0,4650152.0,Syngene’s Q1 net profits up 26% to ₹93 crore,"Syngene, Biocon’s contract research unit, reported 26% increase in net profits to ₹93 crore for Q1, with revenue from operations at ₹808 crore. EBITDA margin stood at 28.3%. Syngene made investments to grow biologics manufacturing and discovery services, while maintaining strong balance sheet and lo…",positive,positive,3.7198284141110127,positive,2.106045589692765,positive
2023-07-26 21:43:30.000,780.95,813.0,766.85,810.0,4650152.0,"Syngene International Q1FY24: Net profit up 26%, revenue surges 25.4%","The first quarter revenue from operations rose 25.4 percent year-on-year (YoY) to Rs 808.1 crore, compared to Rs 644.5 crore in the corresponding period of last fiscal.",positive,positive,3.7198284141110127,positive,2.106045589692765,positive
2023-07-27 10:11:17.000,780.95,813.0,766.85,810.0,4650152.0,Syngene International gains 6% on healthy Q1 numbers,"The firm’s consolidated profit was up 26 percent year-on-year increase at Rs 93 crore, while revenue from operations rose 25.4 percent to Rs 808.1 crore in the June quarter",positive,positive,3.7198284141110127,positive,2.106045589692765,positive
2023-07-31 13:35:45.000,795.0,815.15,792.05,806.2,791671.0,Syngene Q1 Results Review - Healthy Guidance Already Priced In: Yes Securities,Factoring ~$45 million of Zoetis sales in FY24 leads us to believe core research business is not growing more than 12-13%.,neutral,neutral,1.4088050314465466,positive,-0.8343634116192831,neutral
